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Voorwoord 
Het in dit proetschrift beschreven onderzoek werd verricht op de afdeling 
Klinische Fysica van de Dr. Daniel den Hoed Kliniek. Vanzelfsprekend kon dit 
werk slechts uitgevoerd worden met de hulp van velen waarvan ik enkelen 
speciaal wil bedanken. 
Al!ereerst wi! ik mijn promotor Prof. Dr. J.F. Koster en mijn co-promotor 
Dr. W.M. Star bedanken voor hun begeleiding bij het tot stand komen van dit 
proefschrift. 
Willem je semantische nuchterheid en redactionele virtuositeit hebben in 
belangrijke mate bijgedragen tot verheldering van de tekst en de vormgeving van 
dit proetschrift. lk ben je daarvoor veel dank verschuldigd. Een uitspraak als "dit 
is, naar ik aanneem, toch nog niet de definitieve versie van je stukje ?! " was 
voor mij altijd een grote aansporing om de draad weer op te pakken. Je 
enthousiasme, inzichten, suggesties en retorische vragen zal ik in Buffalo 
moeten ontberen. 
Veel van het praktische werk is uit handen genomen door de analisten en niet 
aileen veel handen maar ook een goede steer maken het werk Iicht. Jeanne 
Versteeg wil ik hierbij bedanken omdat ze mij als totodynamisch groentje heeft 
ingewijd in de experimentele aspecten van de fotodynamische therapie (PDT). 
Daarnaast wil ik haar opvolger Otto Speelman bedanken dat hij, wanneer nodig, 
zich zo gemakkelijk voor mijn karretje liet spannen. Maar mijn dank gaat vooral 
uit naar Nynke van der Veen, die samen met mij aan het project DDHK 89-3 van 
de Nederlandse Kankerbestrijding verbonden was. Zander haar was ik 
waarschijnlijk nu nog tluorescentie opnames aan het uitwerken. Veel succes de 
komende vier jaar en bedenk het is gemakkelijker niet te publiceren dan niet te 
promoveren ..... 
Hans Marijnissen wil ik hierbij bedanken, voor de morele steun en 
verbondenheid als lotgenoot, maar vooral om zijn inbreng wat betreft de 
technische aspecten van het onderzoek. lk hoop dat ze begrijpen wat ik bedoel 
als ik daarginds over "verloopbusjes" ga praten. Hugo van Staveren wil ik 
bedanken als collega en als medetorens met wie ik vele barre tochten naar het, 
voor amsterdammers, verre Rotterdam heb ondernomen. Als het nodig was zetfs 
staand in een streekbus. 
Anneke van den Berg-Biok wil ik bedanken voor het tabriceren van vele van de 
kamertjes modellen waarop dit proetschrift steunt en oak voor het overdragen 
van haar kennis en ervaring aan Nynke. Na een begin van wankelen, vallen en 
opstaan staan we nu, oak dankzij jou op eigen benen. 
II 
Jan Nauta en Max Witjes, twee Groningse lotgenoten, wil ik bedanken voor 
hun kameraadschap in het onderzoek. Dankzij jullie vele vragen werd ik zelf een 
stuk wijzer wat betreft de PDT, maar tegelijkertijd ben ik ook een stuk 
zenuwachtiger geworden voor tandartsen. 
Onderzoek doen is vaak improviseren en dat is oak mogelijk geworden door de 
hulp van ondersteunende diensten zeals de instrumentmakerij, de elektronica 
afdeling en de dienst computerondersteuning (Beter bekend als Pc & N). Als iets 
onbetaalbaar was, gewoon niet bestond of niet wilde passen kon ik altijd en als 
het echt moest onmiddellijk bij jullie terecht. lk ben jullie: Henk Elderhorst, 
Aad Melis, Dick van Sluis, Wim Lamprecht, Adrie Bot, Aad van der Heiden en 
Sylvia Verhoef daarvoor zeer erkentelijk. 
lk wil hierbij ook Hans Vuik, Sten Sliwa, Dennes van der Wal en Majo Polak 
van de afdeling medische fotografie bedanken voor hun hulp en geduld bij het 
maken van de mooie opnames die ik heb kunnen gebruiken voor presentaties, 
artikelen en dit proefschrift. 
Het onderzoek is vooral mogelijk geworden doordat nieuwe "stofjes" 
beschikbaar gesteld werden. Daarvoor ben ik met name Johan van Lier, Hans 
Schuitmaker, Giullio Jori en Vincenzo Cuomo zeer dankbaar. 
Van deze mensen gaat mijn dankbaarheid in het bijzonder uit naar Johan van 
lier. Niet aileen omdat hij mijn grootste "dealer" was, maar in het bijzonder 
omdat ik hem mag beschouwen als de teweegbrenger van mijn buitenlandse 
avontuur. lk hoop dat we in de toekomst elkaar nog vaak tegen zullen komen, 
zowel op het wetenschappelijke als het persoonlijke vlak. 
Veel mensen zal ik vergeten zijn met name te noemen, zeals daar zijn aile 
medewerkers van de afdeling klinische fysica en instrumentatie (die mij als 
buitenbeentje in hun midden getolereerd hebben), maar ik ben ze daarom niet 
minder erkentelijk. 
Jacqueline, jij haalde me over om te gaan promoveren en om dat te bereiken 
heb je me telkens weer weten te motiveren door te gaan, met dit boekje als 
resultaat. Aan jou draag ik dit proefschrift op. 
Eric van leengoed 
Amsterdam, 24 februari 1993 
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Chapter 1 
Introduction 
A major task for cancer research lies in the development of tumor specific drugs. 
Usually, toxicity of a drug towards normal tissue is a limiting factor for therapy. 
In photodynamic therapy (PDT) the situation is different. Here, a photosensitive 
dye is administered which is retained by the tissue and after an interval of 
24-48 h is activated by light of appropriate wavelength and dose. 
Photosensitizing dyes have the advantage that in contrast to conventional 
cytostatic drugs they can be selected to be nontoxic in the absence of light. 
Although certain organs such as liver, kidney and spleen may retain high levels 
of photosensitive drug, little toxicity is expected as long as these organs remain 
shielded from light. Another advantage of PDT over conventional types of 
therapy is its dual selectivity. First, some selectivity is obtained by enhanced 
localization of the photosensitizer in tumor tissue compared to normal tissue. 
Secondly, photodynamic damage can be restricted by restricting the irradiated 
area. 
Already at the beginning of the century photodynamic effects on tumor tissue 
were reported for fluorescent dyes like eosin, acridine orange, and porphyrins. 
Skin tumors treated topically with eosin and irradiated with a high light dose, 
sometimes showed tumor regression (von Tappeiner and Jesionek, 1903). 
The actual development of PDT was initiated in the sixties by the work of 
Lipson and Schwarz. During a study to explore the localizing properties of 
hematoporphyrin in neoplastic tissue, a drug called hematoporphyrin derivative 
(HPD) was prepared by Schwarz. Lipson (1961) demonstrated that following 
systemic administration of this preparation, experimental rat tumors could be 
detected by exciting HPD fluorescence with violet light. However, already in 
1913, skin photosensitivity induced by a systemic administration of 
hematoporphyrin was recognized. Meyer-Betz (1913) became famous as he was 
the first to describe the effects of skin photosensitivity after he had 
administered hematoporphyrin to himself. Exposure to sunlight one day later 
resulted in severe erythema and oedema. This skin photosensitivity lasted for 
several weeks. 
The therapeutical applications of PDT became the main subject of 
investigation as it appeared impractical to administer HPD and induce long term 
skin photosensitivity just for tumor localizing purposes. 
The development of suitable light sources such as lasers lead to a renewed 
interest in the therapy. The work of Dougherty et al. (1978) stimulated a 
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worldwide and still increasing interest in experimental and clinical research on 
photodynamic therapy. At present many thousands of patients have been 
treated with encouraging results. 
HPD is a complex mixture of porphyrins and contains hematoporphyrin, 
hydoroxyethylvinyldeuteroporphyrin, protoporphyrin and a hydrophobic fraction 
that localizes in tumor cells. The preparation procedure of HPD is critical and can 
be a source of variation in the final composition of the drug (Dougherty, 1982). 
The hydrophobic fraction, consisting of oligomers linked by ethers and/or esters, 
appears to be responsible for the therapeutic effect of HPD (Dougherty et a!., 
1984; Kessel, 1986). Another problem is that light of 630 nm wavelength, 
which is used clinically to activate the photosensitizer, has only a limited depth 
of penetration. This restricts the tumor volume that can be effectively treated. 
Finally, HPD causes temporary skin photosensitivity. These drawbacks of HPD 
have stimulated a search for better photosensitizers for tumor localization and 
PDT. 
Photodynamic therapy 
Photodynamic therapy is based on the dye-sensitized photooxidation of 
biological matter in the target tissue (Foote, 1990). The dye (sensitizer) is 
administered to the organism and after a certain time an optimum ratio between 
photosensitizer concentration in tumor and normal tissue is reached. The tissue 
containing the dye is then exposed to high dose of light of a wavelength that 
corresponds with an absorption maximum of that dye. Following the absorption 
of light, the sensitizer is transformed from its ground state (singlet state) into an 
electronically excited state (triplet state) via a short-lived excited singlet state. 
The excited triplet can undergo two kinds of reactions. It can react by electron 
transfer with a substrate to form radicals and radical ions, which after 
interaction with oxygen can produce oxidized products (type I reaction). It can 
also transfer its energy to oxygen directly to form singlet oxygen, a highly 
reactive, oxidative species (type II reaction) (Foote, 1990; Moan, 1990). These 
oxidized products can lead to cellular damage and eventually tissue destruction. 
From the above it is evident that PDT effects are oxygen dependent so that 
tissue oxygenation levels play a significant role in PDT treatment effectiveness 
(Sown et a!., 1986). 
To date patients with a variety of malignancies that are accessible to light 
application have been treated by PDT. In the beginning, recurrences or 
metastases in the skin and in easily accessible body cavities (mouth, vagina) 
were treated by PDT (Forbes et a!., 1980; Wile et a!., 1984a; Ward et a/., 
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1982). Later, endoscopic applications were developed for PDT of bladder, lung 
and oesophagus (Benson eta!., 1983; Cortese and Kinsey, 1982; Hayata eta!., 
1984c; McCaughan eta!., 1985). A large number of patients, mostly with lung 
cancer, have been treated by the group of Hayata et al. and they concluded that 
the best results were obtained in treating small ( < 1-2 em) or superficial tumors 
(Hayata eta/., 1984a; Hayata eta!., 1984b; Hayata eta!., 1984c). Larger or 
nonsuperficial tumours probably need to be treated interstitially, using multiple 
fiber afterloading techniques (Marijnissen eta!., 1992). Although in a few cases 
interstitial PDT has been applied clinically, this approach is still in a 
developmental stage. 
Photo sensitizers 
First generation 
HPD can be regarded as a first generation photosensitizer. It was introduced for 
clinical therapy in 1976 at Roswell Park Memorial Institute by Dougherty (1978). 
At present a refined form of HPD is available which has been enriched in the 
photodynamically active fraction (trade name Photofrin II or simply Photofrin"'). 
HPD has attractive properties: tumor localization, photodynamic activity and 
low toxicity. However, as stated above, HPD is not a single compound but a 
mixture of porphyrins and their aggregates. Porphyrins which are both 
monomeric and hydrophillic, show high fluorescence upon excitation but do not 
localize in the tumor cell and appear not to be photodynamically active in vivo 
(Kessel and Chou, 1983). The hydrophobic dimers and oligomers do localize 
within the tumor cell but fluoresce only weakly. The fact that a fraction of HPD 
localizes in a tumor therefore does not directly imply that the tumor will also 
show fluorescence. Specific localization of the drug is not limited to tumor tissue 
alone. Skin and components of the reticuloendothelial system (e.g. liver, spleen 
and macrophages) also accumulate significant amounts of the photosensitizer. 
Experimental tumors growing in liver for example are known to retain less HPD 
than the surrounding normal tissue (Gomer and Dougherty, 1979; Bugelski et 
a!., 1981) 
Therapeutically favourable ratios of porphyrin concentration may be due to 
several mechanisms: 
1. The clearance of hydrophobic porphyrins from the tumor tissues usually 
occurs at a slower rate than from most healthy tissues, possibly due to a 
reduced lymphatic drainage (Dougherty, 1987). 
2. Increased receptor mediated transport of HPD to the cells. Proliferating cells 
often have a high expression of low density lipoprotein (LDL) receptors. This 
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favours the uptake of LDL-bound porphyrins in larger amounts by tumor cells 
than by normal cells (Jori, 1992). 
3. Transfer of porphyrins from plasma to the interstitial space, facilitated by 
greater permeability of tumor vessels for porphyrin carrying macromolecules. 
In order to be activated a photosensitizer must absorb light. The wavelength 
at which a photosensitizer can be activated is determined by its absorption 
spectrum. 630 nm is the wavelength commonly used in clinical PDT with 
porphyrins since this corresponds with the longest wavelength absorption peak 
of HPD. Although shorter excitation wavelengths can have a higher absorption, 
the limited depth of penetration at these wavelengths allows only treatment of 
very superficial lesions. The absorption spectrum does not have to be the same 
as the action spectrum of a photosensitizer. In vivo, it appears that a 5 nm blue 
shift occurs in the action spectrum of HPD so that the excitation wavelength 
should actually be 625 nm (Star eta/., 1990). 
Second generation 
The search for second generation photosensitizers is intended to overcome the 
negative aspects of HPD. Instead of being mixtures like HPD or Photofrin®, 
second generation photosensitizers should be single compounds. They should 
show a relatively high uptake or retention in tumor tissue and have a high 
absorption of light at a wavelength where tissue penetration is high (Fig. 1). This 
way a maximum tissue volume can be treated. Finally, they should fluoresce in 
their monomeric state so that fluorescence indicates the presence of dye that is 
also photodynamically active (MacRobert eta!., 1989). 
HPD induced skin photosensitivity is caused by the long retention of HPD in 
the skin in combination with the strong absorption of violet light. When a 
photosensitizer is used for tumor fluorescence alone, skin photosensitivity 
should be avoided. This can be realized by choosing a photosensitizer that: 
1. Has no photodynamic activity, and/or 
2. Is quickly cleared from the body, and/or 
3. Has only limited retention in normal skin, and/or 
4. Has an absorption spectrum of which the major peaks do not overlap with the 
solar emission spectrum. 
For photodynamic therapy the same possibilities apply except (1) because the 
quantum yield for photodynamical activity should be high. 
The photosensitizers that are discussed in this thesis satisfy one or more of 
the conditions described above. Conditions 1 and 2 may be satisfied by 
Uroporphyrin I, for which tumor retention (EI-Far and Pimstone, 1986) but no 
biological activity (Nelson eta/., 1986) were reported. Acridine red also belongs 
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to this category. This dye; which actually is a pyronine and not an acridine 
(Lillie, 1977) is used for fluorescent labelling of blood platelets in 
microcirculation research (Star eta!., 1985). Conditions 3 and 4 are to a certain 
extent satisfied by phthalocyanines and bacteriochlorine a (Fig. 1 ). These dyes, 
however, have a strong tendency to aggregate in an aqueous environment 
which renders them inactive. 
n 
400 600 
-· 
/ Q ·/ Bocteriochlorins 
/jl ~ / !If\ 
~ P\thalocyooioes 
\Ch1orins 
~ 
Substituted porphyrins 
800 
>om 
10-3 ~ 
c 
.': 
E 
• c 
10-4 ~ 
... 
Figure 1. Diagrammatic representation of the absorption spectrum of a typical metal 
free porphyrin, and of the modifications caused by various structural changes in relation 
to the transmittance of 1 em of human tissue {redrawn after Bonnet and Berenbaum 
11989}) 
In order to overcome aggregation and precipitation, the molecule has to be 
chemically modified, or delivery systems such as liposomes must be used. The 
consequences of these modifications on fluorescence pharmacokinetics and 
photodynamic activity will be discussed in this thesis. 
A new development in photosensitizer delivery is to administer a precursor 
that by itself is not a photosensitizer but causes individual (tumor) cells to 
generate their own photosensitizer. This approach, using an endogenous 
photosensitizer instead of an exogenous one, is also discussed. 
In vivo model system 
The studies reported in this thesis were performed in vivo on skin fold chambers 
with a transplantable tumor growing in subcutaneous tissue of the rat. The 
6 Chapter 1 
model has been developed by Reinhold {1979) for the study of tumor 
microvasculature. It also proved to be useful for the study of the vascular 
effects resulting from PDT treatment {Star et af., 1986). 
The skin fold chamber contains a 0.5 mm thick layer of subcutaneous tissue 
of the dorsal skin placed between two transparent covers, one of which can be 
removed to permit the insertion of tumor tissue {approximately 1 mm3 ). Most of 
the experiments were performed with a transplantable mammary carcinoma. 
During the entire experimental procedure the animals were kept in a 
temperature controlled {32°C) cabinet. The elevated temperature ensures 
adequate tumor growth in the chamber. The ambient light level inside the 
cabinet was reduced to less than 30 pW/cm', providing the animals with a 
proper day/night cycle without causing observable photosensitization. 
When the chamber is placed under a microscope, the veins, arteries and the 
capillary beds of subcutis and tumor tissue can be observed, at low 
magnification. In this way the fluorescence kinetics in blood vessels, tumor and 
subcutaneous {normal) tissue of the chamber following i.v. administration of a 
fluorescent dye can be monitored {van Leengoed et af., 1990). During and after 
the delivery of a treatment light dose the effect of the therapy on the 
vasculature can also be determined. A typical sequence of severe vascular 
effects resulting from PDT starts with arterial spasm followed by ischaemia 
{blanching of the tumor) and a reduction of the red blood cell column diameter in 
the larger venules. The tissues of the chamber become hyperaemic due to the 
dilatation of the capillaries which appear packed with red blood cells. Stasis in 
the larger vessels, which is usually preceded by thrombus formation will also 
occur. After treatment extravasation of blood, especially in the tumor area is 
sometimes observed. lf these vascular effects are maintained over a period of 
more than one day, tissue necrosis can occur. When the vascular effects are 
less severe, the larger vessels usually remain functional and the capillary bed of 
the tissues will recover from the effects of therapy. 
Fluorescence localization 
The advantage of tumor detection by photosensitizer induced fluorescence is the 
possibility to recognize small occult tumors and/or determine the "extent" of the 
disease. Especially tumors that progress from carcinoma in situ, like bladder 
tumors, or which can occur multifocally can be detected using fluorescence 
{Benson eta/., 1982). 
When excited with violet light, the salmon red fluorescence of HPD in tumors 
can be observed with the naked eye. The fluorescence can also be recorded 
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using a (photo)camera and a filter that blocks the excitation light. Detection 
methods like these require relatively high levels of excitation light intensity to 
make the fluorescence observable. Consequently, the excitation light may cause 
undesired photodynamic damage to tissues under investigation. It is therefore 
recommended to use intensified video cameras for fluorescence detection. 
In order to access body cavities for tumor localization, several types of 
fluorescence endoscopes have been developed. Non-imaging instruments have 
been described by Kinsey (1980) and lin (1984). With these systems the 
fluorescence signal is detected during white light endoscopy. The tissue is 
alternately illuminated with white light and with fluorescence excitation light. 
The intensity of the fluorescence signal of HPD is converted into a sound with a 
certain pitch. Tissue autofluorescence levels can distort the detection of HPD 
fluorescence. Autofluorescence is emitted by naturally occurring fluorochromes 
and its intensity increases with decreasing excitation wavelength. This problem 
was recognized by Aizawa (1984) who reported on a system that analyzed and 
displayed the fluorescence spectrum, making it possible to distinguish the 
characteristic HPD fluorescence emission spectrum from the background 
autofluorescence spectrum. HPD fluorescence could also be distinguished from 
autofluorescence by improving the contrast using digital substraction of 
fluorescence images recorded with different emission wavelengths (Profio eta!., 
1986), by using multicolor imaging and contrast enhancement (Andersson et at., 
1987) and even with the help of intensified colour imaging (Brodbeck et at., 
1987). Another technique is based on the fact that autofluorescence does not 
vary much between two excitation wavelengths provided they are not too far 
apart. HPD fluorescence on the other hand, has distinct excitation maxima. The 
image recorded at a wavelength where there is no HPD fluorescence excited can 
then be subtracted from an image where HPD fluorescence is excited using an 
excitation wavelength close to the first one. A system like this has been 
described by Baumgartner (1987) and seems to be very sensitive. 
All fluorescence localization systems mentioned above were designed for the 
excitation and detection of HPD fluorescence using fixed excitation wavelengths 
around 400 nm. However, HPD also has fluorescence excitation maxima at 
500 nm and at 625 nm (Gijsbers, 1986). New photosensitizers that are being 
developed as alternatives for HPD and Photofrin® have different qualities 
regarding their fluorescence excitation and emission. The study of the 
fluorescence properties of fluorescent dyes therefore requires a flexible 
fluorescence excitation and detection system. 
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Fluorescence detection system 
In order to study the fluorescence 
system has been built and 
pharmacokinetics a fluorescence detection 
currently the fluorescent properties of 
photosensitizers can be studied on a routine basis. The system that was first 
used consisted of an expanded low power laser beam exciting the dye in the 
skin fold chamber (Fig 2A). The resulting fluorescence was then detected 
through a high pass filter by an intensified charge coupled device (CCD) camera. 
Currently, the excitation light is obtained from an arc or a halogen lamp and the 
wavelength can be chosen using a range of filters. Dual wavelength excitation 
can be performed simply by exchanging filters (Fig. 2(3)). The excitation beam 
has been coupled into the optical path of the detection system by means of a 
dichroic mirror (Fig. 28). In this way excitation light reflected by the chamber or 
the tissue in the chamber cannot reach the emission filter. This is important 
because this excitation light may cause fluorescence in the emission filter, which 
may disturb the tissue fluorescence image. With the aid of image processing, 
average grey scale values of areas of interest in the image can be calculated. 
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Figure 2. Schematic representation of the first (A) fluorescence detection system and 
the present one (8} which uses a dichroic mirror and excitation and detection filters. (1 J 
Light source, (2) heat reflecting mirror, (3) revolving filter wheel with excitation filters, 
(4) Y-fibre, 15! Leitz Photar lens, 16! high pass filter, {7) CCD camera with image 
intensifier, (8) lens, (9) dichroic mirror, {1 OJ computer with frame grabber and imaging 
software. 
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It is even possible to correct these values for fluctuations in the excitation light 
intensity and for nonuniform spatial response of the optical system using 
simultaneously recorded reference images made of coloured plastic sheets. 
Therapy 
Tumor destruction following PDT is a consequence of specific damage by 
reactive oxygen species resulting in both direct tumor cell death and blood 
vessel stasis. This blood flow stasis is largely responsible for the definitive tumor 
destruction after PDT (Star et a!., 1986; Fingar et a/., 1988; Henderson and 
Fingar, 1987). 
A unique quality of fluorescent dyes that can be exploited during therapy is 
the fact that porphyrins IPhotofrin") as well as phthalocyanines are 
photobleached (photodegraded) by their own photochemical reaction (Henderson 
eta!., 1985; Moan, 1986). This phenomenon can be exploited to increase the 
therapeutic ratio of PDT. The drug dose should be chosen so low that during the 
irradiation the dye concentration in the normal tissue will rapidly be exhausted. 
The effect of a longer irradiation will not increase normal tissue damage whereas 
the higher sensitizer concentration in tumor tissue can still be activated to cause 
tumor necrosis. 
Cellular effects 
Direct cell kill as a result of PDT is caused by damage to the plasma membrane 
(Boegheim et a!., 1987) and mitochondria (Hilf et a!., 1986), but also other 
cellular structures such as lysosomes and microsomes can be damaged. Due to 
the short life-time of singlet oxygen (the main cytotoxic agent of PDT) it 
probably reacts at the site where it was formed (Bachowski eta!., 1991 ), which 
follows the dye as it shifts from a membrane localization to a cytoplasmatic 
localization as a function of time after administration. 
The consequence of photodynamic cellular damage is a rapid loss of cell 
integrity. Associated with such cellular damage is the release of inflammatory 
and immune mediators (Henderson and Dougherty, 1992). These substances are 
potent, fast acting and vasoactive and probably relate to the PDT induced 
vascular damage discussed below. 
The role of direct tumor cell kill is of secondary importance. When tumor cells 
were removed immediately following therapy, cell clonogenicity was not 
affected by the irradiation (Henderson eta!., 1985). Decrease of clonogenicity 
using the explant technique was only observed when the tumor was left in situ 
for a few hours after therapy. 
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Vascular effects 
PDT mainly acts by destroying {tumor) vasculature {Star eta!., 1986; Selman et 
a/., 1984; Fingar et a!., 1988; Henderson and Fingar, 1987). After 
administration photosensitizers are mostly found in the perivascular stroma 
{Bugelski eta/., 1981) and around blood vessels {Carpenter eta/., 1977; Peng et 
a/., 1991a) Therefore, it is to be expected that endothelial cells in the vessel 
walls are damaged by PDT {Berenbaum eta!., 1990). The damage which has 
been directly observed {Star et a/., 1986), occurs already early during light 
treatment and is characterized by vessel constriction and platelet aggregation. 
These vascular effects will lead to blood flow stasis {Henderson and Fingar, 
1987) which causes hypoxia and deprives the tissue of vital nutrients. It is very 
difficult to distinguish direct and indirect effects resulting from therapy. 
PDT leads to mast cell degranulation, release of clotting factors and other 
mast cell derived mediators {Kerdel et a!., 1987). For instance, histamine is 
released which is a powerful vasodilator which increases the capillary 
permeability, allowing leakage of fluids and proteins into the tissue. This can 
explain the edema that is observed after PDT. Histamine also induces the release 
of von Willebrand Factor from endothelial cells exposed to Photofrin® and 
sublethal doses of light {Foster et a!., 1 g91 ). This factor mediates platelet 
adhesion to the vascular subendothelium. Changes in permeability and 
vasoconstriction during PDT are caused by serotonin and also cyclooxygenase 
products including thromboxane {Reed eta/., 1989; Fingar eta!., 1992). 
As was stated before PDT effects are oxygen dependent. The vascular effects 
determine how much oxygen is available during light treatment and therefore 
influence the amount of direct killing of tumor cells. In a hypoxic environment 
cells appear protected from further PDT damage. Tumor oxygenation should be 
maintained during therapy therefore it is important to understand the 
mechanisms that causes these vascular effects. 
As it appears to be impossible to directly kill all tumor cells with HPD-PDT, 
nutritional resupply to remaining viable tumor cells should be prevented. It is 
therefore probably necessary to "sterilize" a margin of normal tissue vasculature 
about the tumor {Fingar and Henderson, 1987). 
Scope of this thesis 
Photosensitive dyes have great interest because of the attractive combination of 
fluorescence imaging and photochemical destruction of tumors. When detected 
early, tumors are more easy to treat, usually respond better to treatment and 
there is a reduced risk of spreading of the disease. If a reliable fluorescence 
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detection technique were available it could be possible to "screen", on a routine 
basis, people who are at risk for developing a tumor. 
Drawbacks of photosensitizers like HPD and Photofrin® such as prolonged skin 
photosensitivity and low absorption at clinically relevant wavelengths lead to the 
search of new photosensitizers. A number of fluorescent dyes have been 
proposed as second generation photosensitizers. In this thesis 13 administered 
dyes and one endogenously generated dye will be discussed with respect 
fluorescence pharmacokinetics and photodynamic activity. An in vivo skin fold 
chamber model was used to study these properties. 
Chapter 2 discusses aspects of fluorescence pharmacokinetics of 5 
fluorescent dyes: HPD, Photofrin II (Ph II), Up I, AR and AIPhcTS. HPD and Ph II 
are photosensitizers that currently undergo clinical evaluation (presently Ph II is 
known as Photofrin"'). Uroporphyrin I (Up I) and acridine red (AR) are hydrophillic 
dyes which appear photodynamically inactive but which might have tumor 
localizing qualities. Finally, aluminum phthalocyanine tetrasulphonate (AIPhcTSL 
a commercially available phthalocyanine mixture studied as a potential "second 
generation" photosensitizer. Because of improved photosensitizer qualities with 
respect to wavelength absorption and skin photosensitivity, phthalocyanines 
have been investigated more in detail in Chapters 3, 4 and 5. In an aqueous 
environment phthalocyanines have a tendency to aggregate and become 
inactive. In order to render them more hydrophillic, sulphonate groups can be 
added to the molecule. Chapter 3 describes the fluorescence pharmacokinetics 
of six phthalocyanines differing in central metal ion and degree of sulphonation. 
The photodynamic activity, especially the vascular effects of these six dyes are 
investigated in Chapter 4. A different approach in administering hydrophobic 
dyes is to use liposomes as a delivery system. In Chapter 5 zinc phthalocyanine 
administered in this way has been studied. In Chapter 6 bacteriochlorine a (BCA) 
is studied for its photosensitizing properties. This dye has an absorption 
maximum at 760 nm. It therefore can be excited for therapy at a wavelength 
where tissue penetration of light is about twice that at 630 nm used for 
porphyrin activation. Theoretically, the treatment volume can thus be increased 
considerably. Whereas the previous chapters focused on exogenous fluorescent 
dyes, chapter 7 describes the use of endogenously generated porphyrins for 
PDT. This is a new approach that uses a photodynamically inactive precursor of 
heme called 5-aminolevulinic acid (ALA). In (tumor) cells this precursor is 
converted into the photosensitizer protoporphyrin IX (PpiX). 
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Abstract 
Using fluorescence imaging, the tissue localizing properties of five 
photosensitizers were studied in vivo for tumors in "sandwich" observation 
chambers and for tumors growing on thigh muscle. The preliminary results 
indicate that of three photodynamically active dyes tested (hematoporphyrin 
derivative, Photofrin II, and aluminum phthalocyanine tetrasulphonate, the 
phthalocyanine possesses the best tumor localizing properties. This makes it 
possible to combine tumor fluorescence detection and photodynamic therapy 
with reduced skin photosensitivity. The two photodynamically inactive dyes 
tested (uroporphyrin I and acridine red) may be useful for application in 
fluorescence imaging to localize superficial tumors without inducing skin 
photosensitivity. In particular, acridine red has remarkable tumor localizing 
properties, but is rather toxic. 
introduction 
Interest in the use of photosensitizers for tumor localization and tumor therapy is 
steadily increasing (Dougherty, 1987; Manyak et a!., 1988). In clinical 
photodynamic therapy (PDT), the drugs which are almost exclusively used are 
hematoporphyrin derivative (HPD) or a purified version (enriched in active 
material) with the trade name Photofrin II (Phil). Tumor localization using HPD 
fluorescence was first described by Lipson (1961). This application is particularly 
interesting because of the potential to detect early cancer (Profio et a/., 1983; 
Benson et a!., 1982; Gluckman and Wiessler, 1986). A disadvantage of HPD 
and Photofrin II is that both cause prolonged skin photosensitivity. This is a 
major reason for the current search for improved photosensitizers (Dougherty, 
1987). In particular, a fluorescent dye that is exclusively used for tumor 
localization should not make a patient photosensitive over a long period of time. 
Therefore we have begun a study of the tumor localizing properties of 
photosensitizers. Some preliminary results are reported in this paper. 
Materials and methods 
Animal Model 
Tumors were transplanted into the subcutis of 18 weeks old female WAG/Rij 
rats in transparent observation chambers ("skin fold chamber") (Reinhold et a!., 
1979; Star et a!., 1986). The tumors were isogeneic mammary (RMA) 
carcinoma and incidentally rhabdomyosarcoma (RH). One photosensitizer 
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(acridine red) was also studied in isogeneic squamous cell carcinoma (SCC) and 
in a human lung tumor (Hl Tl in immunosuppressed rats. As selective tumor 
fluorescence depends on the drug retention in surrounding normal tissue, 
localization was also documented for tumors (about 3 mm in diameter) growing 
subcutaneously on thigh muscle in the same animal 24 h post injection (p.i.) of 
the drug. 
Photosensitizers 
Five dyes were studied; HPD (Quentron, Adelaide, Australia) and Phil (QLT, 
Vancouver, British Columbia, Canada) because of their current clinical use. 
Uroporphyrin I (Upl, Porphyrin Products) is photodynamically inactive (Nelson et 
a/., 19861 and clears quickly from the body. Aluminium phthalocyanine 
tetrasulfonate (AIPhcTS, Porphyrin Products) belongs to a promising class of 
new photosensitizers for PDT (Dougherty, 1987). Acridine red (AR, Koch light) 
is a pyronine used in microcirculation research to !abel platelets and leucocytes 
(Tangelder et a/., 1982). No photodynamic activity was noted in observation 
chambers (10 mg AR/kg, 218 J/cm2 of light at 514.5 nm). 
Excitation fight 
As an Argon laser was available (Spectra Physics 1711 and 514.5 nm is a 
suitable wavelength, this was used to excite the fluorescence of all dyes except 
AIPhcTS. For the latter, red light of 608 ± 2 nm was used from a dye laser 
(Spectra Physics 3758 with 4-dicyanomethylene-2-methyl-6-p-di-
methylaminostyryi-4H-pyran (DCMII. yielding a relatively high emission intensity. 
Other workers have used a nitrogen laser (Anderson-Engels et a/., 1988) at 
337 nm for excitation and observed that PhcTS emits less fluorescence light 
than Phil. The 608±2 nm wavelength is convenient, as it can be used for 
fluorescence excitation as well as for PDT. Furthermore, a long wavelength is 
preferred to excite fluorescence, because this reduces autofluorescence, 
improving the contrast. This wavelength works well with our model system, but 
may not be suitable for detection of very superficial tumors. An excitation light 
intensity of 0.1 mW/cm2 was used. This generated a sufficient fluorescence 
signal tor detection with our system and reduced the risk of unwanted PDT 
damage to practically zero for all the dyes studied. 
Imaging system 
An intensified charge coupled device (CCD) video camera (HTH Holland) was 
used with a Photar macro lens (Leitz) and an OG570 or OG665 long pass filter 
to block the excitation light. Video signals were processed by a frame grabber 
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(PC vision plus) and a PC-based image analysis program called TIM. 
Experimental Procedure 
Animals were anaesthetized using Hypnorm (Janssen Pharmaceutics) and placed 
on a temperature-controlled holder, fixed to a special stage, allowing exact 
(re)positioning of the chamber for recording and subtraction of successive 
images. After recording an autofluorescence image, dye was injected into a tail 
vein and the fluorescent angiogram was monitored. Fluorescence recordings 
were measured at a number of intervals up to 2 h and after 24 h p.i. The 
fluorescence of tumors growing on thigh muscle was observed and recorded 
after opening and removal of the overlying skin, yielding tumor images with a 
background signal different from subcutis. Table 1 shows the various dyes 
tested and the experimental parameters. 
Table 1. Summary of the experimental parameters in the tissue fluorescence imaging 
study using different dyes. 
Dye Dose Number of Ruorescence excitation 
(mg/kg) Animals Wavelength lrradiance 
(nm) (mW/cm2 ) 
Uroporphyrin I 15 5 514.5 0.1 
HPD 15 10 514.5 0.1 
Photofrin II 15 6 514.5 0.1 
AIPhcTS 2.5 20 608 ± 2 0.1 
AR 2 or 10 25 514.5 0.1 
Different numbers of animals were employed because some drugs were used for 
fluorescence only, whereas for others the photodynamic activity was also studied (not 
reported in this paper). 
Image scoring 
The images were digitized and then evaluated for differences between tumor 
and normal tissue fluorescence. Tumor selectivity was visually rated positive 
when the fluorescence of the tumor area significantly exceeded that of the 
surrounding subcutis (i.e. a minimum of 15 npixel" values out of a maximum 
value of 256). The rating was performed by at least two observers. For each 
interval, after subtraction, each observation chamber (animal) was classified in 
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one of three categories: tumor fluorescence larger (T>Sub), equal to (T=Sub) 
or less than (T <Sub) fluorescence of subcutis. Changes in fluorescence over 
time, obtained from subtracted images, are denoted by AT and A Sub. 
Selectivity Score 
100% 
80% 
60% 
40% AIPhcTs 
20% 
5 15 30 60 120 24 h 
Time p.i. (min.} 
Fig. 1. Selectivity of tumor fluorescence relative to that of the surrounding subcutis in 
the chamber model for four of the dyes tested. The vertical axis shows the percentage 
of animals which exhibit tumor fluorescence exceeding subcutis fluorescence !T> Sub). 
Results 
The excitation light intensity of 0.1 mW /cm2 does not have observable effects 
on the (micro)vasculature, even after long periods of continuous observation 
(1 h). Since the RMA and RH tumors show similar fluorescence kinetics with all 
five dyes, the data from the two tumor types are pooled for presentation in 
Fig. 1, where selective tumor fluorescence (T>Sub) is expressed for four of the 
dyes tested. 
After intravenous injection (5 min. p.i.), Up! is selective in all cases. However, 
after longer intervals, this selectivity is lost and the tumor may even show less 
fluorescence than the subcutis (60 min.). At 24 h, the tumors are 
indistinguishable from the subcutis. After injection of Phil, selective fluorescence 
is observed for the first time after 30 min. and after 120 min. only 50% of 
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cases show selective fluorescence. At 24 h the tumor is indistinguishable from 
the subcutis in all cases except one. HPD, unlike Phil, shows selectivity shortly 
after injection, but never exceeds 40% of cases. The observed selectivity is lost 
at 24 h. At this time, in 60% of cases the fluorescence of the subcutis exceeds 
that of the tumor embedded in it. Tumor fluorescence of AIPhcTS gradually 
increases, reaching 100% selectivity at 60 min. p.i. (Fig 2). 
On the following day selectivity is still observed in 50% of cases. Acridine red 
is 100% selective immediately after injection in all cases (Fig. 3), for all tumor 
types tested (RH, RMA, SCC and Hl T) and for both AR concentrations; it is 
therefore not included in Fig. 1. AR is rapidly cleared from the circulation. The 
highest dose (1 0 mg/kg) causes mortality in some cases. Therefore 2 mg/kg was 
used in later sessions. The cause of this mortality is under investigation. 
Data on the fluorescence dynamics of the dyes up to 120 min. p.i. are 
presented in Fig. 4. Upl shows a selective increase in tumor fluorescence in all 
cases during the first interval (5 min. autofluorescence). During the next two 
intervals the only increase observed is in the subcutis; in the last two intervals 
there is no difference between the fluorescence increase at the tumor and 
subcutis sites. 
Figure 2. 
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Fig. 2. Sequence of fluorescence images of AIPhcTS (2.5 mg/kg) in the chamber model 
(diameter, 9.5 mm): {aJ autofluorescence; tbJ 5 min. p.i., full development of the 
angiogram; lcJ 15 min. p.i.; ldJ 30 min. p.i., gradual increase of fluorescence in tumor 
and decrease in blood vessels; (e) 60 min. p.i.; (f) 120 min. p.i., tumor fluorescence is 
stl11 increasing, blood vessel fluorescence is decreasing; (g) 24 h p.i., fluorescence 
intensity is highest at the tumor boundary. Selectivity is decreased due to the 
fluorescence level in the subcutis, showing a negative fluorescence image of a large 
blood vessel; (h) 24 h p.i. and after a PDT treatment dose of 450 J at 608 nm. Marked 
photobleaching can be observed. 
The fluorescence of Phil remains almost constant. In most cases no distinction 
can be made between the fluorescence increase at the tumor and the subcutis 
sites. In contrast, HPD shows an interesting selective increase in the tumor fluo-
rescence during the first 30 min. p.i., reaching a 100% selective increase 
between 5 and 15 min. After 30 min. the increase is restricted to the subcutis 
or becomes equal for the tumor and subcutis sites. AIPhcTS also shows a peak 
selectivity at the 5-15 min. interval. An increase in selectivity occurs in all 
intervals but never reaches 100%. 
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Almost immediately after i.v. injection, the fluorescence of the blood vessels 
decreases for all dyes except Phil. Both photodynamically inactive dyes (Up!, 
AR) show an immediate decrease in fluorescence in the blood vessels after the 
development of the angiogram. At the same time there is a dramatic increase in 
tumor fluorescence and a dispersion of fluorescence in the subcutis. The 
fluorescence of HPD and AIPhcTS in the blood vessels decreases more 
gradually. In contrast, Phil shows an increase in fluorescence in the circulation, 
in one case even up to 2 h p.i. All photodynamically active dyes show an 
increase in fluorescence in the subcutis up to 24 h p.i. An interesting 
observation at this interval is that in 50% of cases for both HPD and AIPhcTS, 
the fluorescence intensity at the tumor boundary is higher than that in the tumor 
volume (Fig. 2g). In this context, it should be noted that the observation 
chamber shows a cross section of the tumor, whereas in clinical practice we 
usually observe a tumor boundary. 
The images taken from the tumors growing on thigh muscle at 24 h p.i. show 
selective fluorescence for Up!, HPD, Phil, and AIPhcTS. With AR at a dose of 
10 mg/kg, selectivity for tumor on muscle is partially lost at day 1 and in some 
cases the animals do not survive this drug dose. Therefore a lower dose 
(2 mg/kg) was chosen; at this dose 100% selectivity for tumor on muscle is 
maintained only during the first 30 min. p.i. At day 1, in 30% of cases, the level 
of fluorescence from the muscle exceeds the fluorescence of the tumor. This is 
in contrast with the other dyes where the tumor to muscle ratio at 24 h shows 
an increase compared with that obtained shortly after injection. 
Discussion 
There is a striking difference between the selective fluorescence of tumors 
growing in the subcutis (observation chamber) and tumors growing on thigh 
muscle. It appears that lipophilic dyes (HPD, Phil, AIPhcTSl are retained more in 
skin than in muscle (Eckhauser et a!., 1987). When a tumor showing less 
fluorescence than the subcutis in the observation chamber is removed and 
placed on thigh muscle of the same animal, selective fluorescence is always 
observed. 
Photodynamic therapy is usually performed 24 h after drug administration for 
murine tumors and 48-72 h for human tumors; these may not be the optimum 
intervals. The present study shows that the optimum interval for tumor 
localization using selective tumor fluorescence may be considerably shorter. This 
has been noted previously by Benson (1982) in their study of HPD fluorescence 
in human bladder. 
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Fig. 3(a}. White light photograph of a human lung tumor in an immunosuppressed rat in 
an observation chamber. The blood vessels surrounding the tumor (diameter, 2.5 mm) 
can be clearly seen as well as clusters of fat cells to the left and right of the tumor. (b). 
Fluorescence image of the same tumor a few min. after administration of acridine red 
110 mg/kg}. 
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Fig. 4. Fluorescence dynamics of Up!, Phi/, HPD and A!PhcTS in the chamber model up 
to 120 min. p.i. The scores (vertical axes, percentage of animals) are obtained by subtr-
action of images at given intervals (horizontal axes). Numbers indicate the time fmin.J 
p.i.; au, autofluorescence image before drug injection. A selective increase in tumor 
fluorescence (11T>l:iSub) is given a positive score. An equal increase (.b.T=t::..Sub) and a 
smaller increase in tumor fluorescence than normal tissue fluorescence (AT<.D.SubJ are 
given a negative score. 
In particular, AIPhcTS appears to be a selective tumor localizing material at rela-
tively short intervals p.i., even in the subcutis. Since this drug causes little skin 
photosensitivity on exposure to sunlight (Roberts et a/., 1989), it seems a 
promising photosensitizer for PDT and tumor detection. 
According to Fig. 1, no real maximum develops for HpD up to 120 min. p.i. 
and selectivity never exceeds 60%. However, for Phil a maximum score occurs 
somewhere between 1 h and 24 h. Long-term observations, not included in this 
paper, indicate that this maximum occurs 3-4 h p.i., in agreement with other 
workers (Svanberg eta!., 1986). A unique phenomenon is the increase in blood 
vessel fluorescence up to 1 h p.i. of Phil. The dimers and oligomers in Phil do 
not fluoresce (Dougherty, 1987), but may be broken down in the cells to pro-
duce fluorescent species (Kessel, 1986). Does this also occur with Phil in blood? 
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Abstract 
The fluorescence pharmacokinetics of a series of metallosulphophthalocyanines, 
chelated with either aluminum or zinc and sulphonated to different degree, was 
studied by fluorescence measurements in vivo. Dyes were administered 
systemically to female WAG/RIJ rats with an isogeneic mammary carcinoma 
transplanted into the subcutis in a transparent observation chamber located on 
their backs. Following an i.v. injection of 2.5 pmol/kg of the dye, fluorescence 
dynamics was observed up to 7 hours post injection. The phthalocyanines were 
excited at 610 nm with a power-density of 0.1 mW/cm2 without causing 
photodynamic damage to the vasculature. Fluorescence was detected above 
665 nm using a fluorescence imaging system based on an image intensifier. Dye 
retention in the blood vessels and tumor tissue was expressed as ratios relative 
to the fluorescence signal of the surrounding subcutaneous tissue. 
Phthalocyanines chelated with aluminum gave the highest fluorescence signal 
with tumor-over-subcutis ratios of up to a value of 4. The zinc complexes 
exhibited the highest vascular-over-subcutis ratios with maximum values 
exceeding a value of 6. They also displayed the longest retention times in the 
vascular system of well over 7 hours. Overall, decreasing the degree of sulp-
honation of the metallophthalocyanines results in lower tumor-over-normal tissue 
fluorescence ratios and furthermore aluminum- based dyes seem superior tumor 
localizers over zinc-based dyes. The advantages of phthalocyanines over 
porphyrins with respect to tumor localization and photodynamic therapy are dis-
cussed. 
Introduction 
Photodynamic therapy (PDT) is an experimental cancer treatment modality which 
combines the photosensitizing properties of selected dyes with their tumor 
retention. Excitation of the dye with light of an appropriate wavelength and dose 
results in the formation of cytotoxic species and subsequent tumor necrosis. 
This excitation of the photosensitizer can also induce fluorescence at a specific 
wavelength and it is this property of hematoporphyrin derivative IHPD) (Lipson 
eta!., 1961) that resulted in the earliest clinical application of HPD, namely as a 
tumor localizer. In the following period, however, most of the attention for HPD 
was drawn to the therapeutical features of the dye. Benson 11982), two 
decades later, demonstrated that HPD not only displayed fluorescence in 
malignant tissue but also localized in dysplastic and neoplastic bladder mucosa. 
From then on attention for HPD expanded again the direction of the diagnostical 
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properties of the dye. Refinement of the technical aspects of fluorescence 
detection resulted in the development of a number of sophisticated detection 
devices (Profio et a!., 1986; Andersson et a!., 1987; Brodbeck et af., 1987; 
Rogers et af., 1990). Currently, by combining these detection devices with state 
of the art endoscopy, clinicians are capable of detecting the very weak coral-red 
porphyrin fluorescence not only on the exterior but on almost every internal sur-
face of the human body including the aerodigestive tract, intestines and bladder. 
Following systemic administration of therapeutical drug doses of HPD, a 
persistent skin photosensitivity is observed that may last at least up to 4-6 
weeks. This is considered one of the major side effects of PDT based on HPD or 
its purified version Photofrin®, currently under clinical investigation, and this has 
prompted a worldwide search for new photosensitizers for PDT of malignant 
disorders (van Lier et af., 1987; Kessel, 1990). Phthalocyanines have received 
considerable attention as "second generation" photosensitizers for PDT (van 
Lier, 1990; Ben-Hur and Rosenthal, 1985; Spikes, 1986). They can be modified 
chemically, thereby altering their photophysical and pharmacological properties 
in a controllable fashion. 
In contrast to the porphyrins currently in use, the dyes can be prepared as 
single products, they are relatively stable and have strong absorption maxima in 
the red region of the visible spectrum (650-700 nm) where the tissue penetrati-
on of light is relatively high (Brasseur et af., 1987; Bown et af., 1986; Peng et 
a!., 1991 b). The phthalocyanines show deep red fluorescence upon excitation 
and this fluorescence probably correlates with the presence of the photoactive 
monomers (MacRobert et a!., 19891 whereas the fluorescent monomers of 
hematoporphyrins are not relevant for photodynamic therapy (Kessel, 1982; 
Kessel, 1986). Several analogues of MPcS, have a preference for tumor tissue 
and amphiphilic derivatives have been shown to have a good potential to inflict 
direct cell kill (Henderson and Bellnier, 1989). Furthermore, skin photosensitivity 
induced by the dyes is low compared to Photofrin® (Tralau et af., 1989). 
Unsubstituted phthalocyanines are insoluble in water which makes them 
unattractive for systemic (i.v.) administration (Berg et af., 1989). Sulphonation 
of the molecule is one way to overcome this problem. 
The effect of the degree of sulphonation of phthalocyanine on their 
pharmacokinetics has been studied using 14C (Rousseau et af., 19901 and 65Zn 
radiolabeled analogues (Scasnar personal communication) and structure-activity 
relationships have been advanced (Paquette and van Lier, 1992). We now report 
on the fluorescence dynamics and localizing properties, of a series of six 
differently sulphonated Zn 2+- and AI'+- phthalocyanines using an in vivo skin 
fold chamber model. 
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Materials and Methods 
Photosensitizers 
Metallosulphophthalocyanines (MPcS") were prepared via the condensation 
method using zinc acetate or anhydrous aluminum chloride as the metal source 
and various proportions of sulphophthalic acid/phthalic acid (Ali eta/., 1988). 
Differently sulphonated fractions were obtained after chromatography on a 30 
em long by 2 em ID medium pressure column packed with C-18 reverse phase, 
particle size 25-40 pm (Machery-Nagel, Duren, Germany) eluted with a gradient 
of methanol and 10 mM acetate buffer, pH = 5. If required, samples were 
further purified by HPLC on a semi-preparative (25 em long by 0.94 em ID) 
reverse phase C-18 column packed with ODS-2 spherisorb 5 pm (CSC, 
Montreal) operated at 2 ml min·' with a linear gradient (55 min) of 0-95 o/o 
methanol in 10 mM phosphate buffer, pH = 5. The latter system was also used 
for the analysis of sulphonated fractions in conjunction with an oxidative 
degradation assay to confirm the degree of sulphonation. The disulphonated 
MPcS2 were enriched in derivatives with two adjacent sulphonate groups. 
Cremophor El (Sigma) was added to the MPcS, and MPcS2 in order to prevent 
aggregation and bring them into injectable solutions. Final MPcS" concentrations 
were determined spectroscopically after a 1:100 dilution of the sample in DMF, 
taking € = 2.5 105 M1 em 1 at Am~ = 675 nm. 
Skin fold chamber animal Model 
Twelve weeks old female WAG/Rij Rats, weighing approximately 110-120 g 
were purchased from ITRI-TNO, Rijswijk, The Netherlands. During a three week 
preparation period, a layer of subcutaneous tissue from a dorsal skin flap was 
mounted in a skin fold chamber (Reinhold et a!., 1979) also known as the 
"sandwich chamber". A maintenance dose of antibiotics (Pentrexii: 
Bristol-Myers, Weesp, Holland and Garamycin, Essex laboratories, Heyst-op-
den-Berg, Belgium) was administered for protection against bacterial infection 
during this period. The final step in the procedure was the implantation of 
approximately 0.5 mm3 of an isogeneic RMA mammary carcinoma into the 
chamber. Tumor growth, the general condition of the chamber and the 
circulation were followed using a microscope at low magnification. The animals 
were kept in a temperature controlled cabinet at 32°C with a 12/12 hour 
light/dark interval. The elevated environmental air temperature determines the 
temperature of the chamber and is therefore a prerequisite for tumor growth. 
After photosensitization the animals were kept under subdued light conditions 
(<30 pW/cm2 ). The chamber model enabled in vivo observations of the 
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fluorescence dynamics of an i.v. administered fluorescent dye in subcutis, tumor 
tissue and blood vessels for the duration of the experiment (up to 24 hours p.i.). 
Through all procedural steps Hypnorm® (fluanisol/fentanyl mixture, Janssen 
Pharmaceutics, Beerse, Belgium) was used as a general anaesthetic. 
Fluorescence detection 
Phthalocyanines were excited at 610 nm with 0.1 mW/cm' of light from an 
argon-dye laser system (Spectra Physics system 171 L with DCM 
(4-dicyanometyhlene-2-methyi-6{P-dimethylaminostytyl)-4H-pyran) as the lasing 
dye. Fluorescence was detected through a high-pass filter transmitting light 
above 665 nm (Schott RG 665). 
The imaging system was based on a two stage image intensifier with a 25 
mm Photar macro lens (Leitz) coupled to a CCD (Charge Coupled Device) camera. 
The resulting video images were digitized on a pc-based framegrabber (Pc-Vision 
Plus), averaged over 16 frames to improve the signal to noise ratio and stored 
on disk for further processing. The system digitizes 256x256 picture elements 
(pixels). Average grey scale values of the area of interest, i.e. tumor, vessel or 
subcutaneous tissue, were calculated using a pixel measurement program of our 
own design, based on image processing software called TIM (Difa Measuring 
Systems B.V., Breda, The Netherlands). In order to determine the level of 
fluorescence in the circulation, an area of the largest vein in the chamber was 
chosen. 
Experimental procedure 
Experiments were performed after the tumors in the skin fold chamber had 
grown to about 3 mm in diameter and when adequate circulation in both 
subcutaneous and tumor tissue was observed. 
The animals were sedated and placed on a temperature controlled ( ~ 30°C) 
positioning stage, allowing careful positioning of the animal under the camera 
using a specially designed imaging program. An (auto)-fluorescence recording 
was made and subsequently the dye, using a dose of 2.5 pmol/kg, was 
administered via a tail vein of the animal. Fluorescence images of the chamber 
were recorded at various time intervals from 5 min to 24 h p.i. For each 
photosensitizer the fluorescence data of 6 animals were collected. At the 24 h 
interval the animals received a therapeutic light dose. The resulting 
photodynamic effects will be discussed in a forthcoming paper. 
28 Chapter 3 
Fig. 1. Digitized fluorescence images of the skin fold chamber containing a mammary 
carcinoma at 5 (A), 10 (8), 60 (C) and 360 10) min p.i. of 2.5 pmol/kg phthalocyanine, 
(1.1) ZnPcS2 (1.2) AIPCS4 • 
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Results 
Two extreme fluorescence patterns were observed in the skin fold chamber 
using the various Pc dyes (Fig. 1.). In the case of the ZnPcS2 (Fig. 1.1) the 
vessels are clearly delineated immediately post injection (p.i), with the 
fluorescence intensity slowly decreasing with time. Only moderate increase of 
fluorescence in the tumor region is observed during the first hour, and little 
fluorescence remained in either the vessels or the tumor at 6 h p.i. In contrast, 
the AIPcS4 (Fig. 1.2) showed hardly any fluorescence in the circulation following 
i.v. administration of the dye whereas immediate fluorescence of the tumor 
region is evident, persisting at least 6 h p.i. The fluorescence distribution of the 
remaining dyes was less pronounced, with varying vascular vs tumor 
fluorescence intensities and the dynamic of all six dyes studies are summarized 
graphically in Fig. 2. Grey scale values are averaged in an area of interest 
selected over the tumor, blood vessel and surrounding subcutis, and expressed 
as ratios relative to the surrounding subcutis i.e. tumor-to-normal tissues (TiNT) 
and blood vessel-to-normal tissue (BViNT) ratios. The average fluorescence 
values of the subcutis alone are also presented on these graphs (grey scale 
values on right Y-axis) to demonstrate the influence of the fluorescence of the 
subcutis on the tumor and blood vessel ratios. 
The TiNT fluorescence ratio of ZnPcS 4 (Fig. 2A) remains higher than 2 up to 
420 min p.i. whereas the BViNT ratio exceeds 6 at 5 min p.i., representing the 
highest fluorescence signal in the blood vessel observed for any of the dyes 
tested. The BViNT value decreases rapidly over the next 3 h while the 
fluorescence of the subcutis increases only slightly during the same period. 
Accordingly, the latter can only partly be responsible for the decrease of the 
BViNT ratio. 
Compared to the ZnPcS4 , the AIPcS4 (Fig. 28) reaches higher TiNT values of 
almost 4, whereas for ZnPcS4 , fluorescence persists for extended periods of up 
to 360 min. In contrast, the fluorescence peak of the AIPcS4 in the blood vessel 
is the lowest observed for all six dyes tested with BViNT values, after a high of 
2.2 at 5 min, dropping rapidly to unity over the next 2 h. Judging from the 
fluorescence of the subcutis the dye has a very short retention time in the 
circulation. After an initial increase, the BViNT ratio remains stable, suggesting 
that tumor tissue accumulates the dye at approximately the same rate as the 
subcutis. At later time intervals (t ;, 240 min) a loss of tumor selectivity is 
observed, but only at 24 h p.i. can the decrease in TiNT values be attributed to 
the increasing normal tissue fluorescence. 
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Fig. 2. Fluorescence kinetics in tumor tissue, blood vessel and background (subcutis) as 
a function of time after i. v. administration of differently sulfonated MPcSn. The left Y-
axis refers to the bar plot of tumor-to-background IT/NT} and blood vessel-to-
background (BV/NTJ ratios. The shaded area represents the fluorescence levels in the 
subcutis (right Y-axisJ 
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like the ZnPcS4 , the disulphonated ZnPcS, (Fig. 2Cl exhibits strong fluorescence 
in the blood vessels with BV/NT values of 4.2 at 15 min p.i. 
Tumor tissue fluorescence is low, with T/NT ratios reaching a maximum of 
almost 2 at about 60 min p.i. The changes in background fluorescence are less 
pronounced than those observed with ZnPcS4 and the increase in grey value can 
account for the decrease in TiNT and BV/NT ratios. 
Similar to the AIPcS4 , the disulphonated AlPeS, (Fig. 20) exhibits high tumor 
fluorescence, with TiNT ratios remaining well above BV/NT values. Maximum 
TiNT ratios of 4 are reached at 240 min p.i., combined with low normal tissue 
fluorescence. The peak of the BV/NT signal of the AlPeS, is higher than that 
observed with AIPcS4 • The increase of fluorescence in the subcutis is less 
striking than that observed with A!PcS4 and this cannot account for the 
decrease in selectivity of tumor fluorescence at intervals ;,; 300 min p.i. 
The monosulphonated ZnPcS, (Fig. 20) displays the highest normal tissue 
fluorescence of all Pc's tested. The selectivity of tumor fluorescence is 
somewhat lower than that observed with the ZnPcS2 , and like in the case of the 
latter, TiNT values remain stable and < 2 during the observation period. 
Fluorescence in the circulation is high and persistent resembling the profiles 
observed with the other ZnPcS". 
Finally, tumor fluorescence observed with the monosulphonated AlPeS, (Fig. 
2F) is also low with T/NT values showing some selectivity only after 60 min p.i. 
Among the AlPeS" tested, the AlPeS, is the only dye where the BV/NT maxima 
exceeded the maximum values of the T/NT ratios, while exhibiting the lowest 
subcutis fluorescence. 
Discussion 
In the present study we have evaluated the tumor localizing properties of 
differently sulphonated zinc and aluminum phthalocyanines through 
quantification of the fluorescence of the dyes in a skin fold chamber. In contrast 
to HPO and Photofrin®, where enhanced tumor fluorescence relative to normal 
tissue could be observed in our model in only 40-60 % of the cases studied (van 
Leengoed et a!., 1990), all phthalocyanines demonstrated consistently good 
localizing properties. However, the aid of a detection system is needed as the 
sensitivity of the eye decreases in the red region of the visible spectrum where 
phthalocyanine fluorescence is emitted. 
Marked differences in tissue selectivity related to the chemical structures of 
the various dyes were observed and both the nature of the central metal as well 
as the overall hydrophobicity of the Pc structure were found critical factors in 
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directing the selectivity of the dyes. Our model allowed us to quantify 
fluorescence in the tumor tissue and blood vessels and in order to permit direct 
comparison of these data, fluorescence at these sites are presented as ratios to 
subcutis fluorescence (Fig. 2). 
Decreased hydrophobicity, i.e. increasing the number of sulphonate groups, 
favours tumor localization of the MPcS, and particularly the tetra and 
disulphonated aluminum complexes gave high TINT ratios of up to 4 combined 
with a low background (subcutis) fluorescence and low BV/NT ratios. Since the 
background fluorescence of the disulphonated derivative is substantially lower at 
0.5 - 1 day p.i. than that observed for the tetrasulphonated derivative, the 
AIPcS2 provides the most favourable fluorescence ratios for tumor localization. 
The ZnPcS, in general gave higher subcutis fluorescence than the AlPeS series 
combined with higher BV/NT ratios and only the ZnPcS4 scored some tumor 
selectivity with T/NT ratios > 2. Overall the following T/NT rank order was 
observed AIPcS4 ;;: AlPeS, > ZnPcS4 > ZnPcS 2 > AlPeS, > ZnPcS,. Thus, 
overall tumor selectivity decreases with decreased levels of dye sulphonation 
and by changing from a trivalent central metal ion Al 3 + to the divalent Zn2 +. 
Similar tumor uptake kinetics have been observed using a series of radioactive 
labelled [65Zn]ZnpcS derivatives (Scasnar personal communication) suggesting 
that the observed fluorescence distribution patterns represent actual dye 
dynamics. 
A somewhat inverse correlation between Pc structure and fluorescence is 
observed in the case of the blood vessels. BV/NT ratios diminish in the following 
order ZnPcS 4 > ZnPcS, > ZnPcS2 > AlPeS, > AIPcS2 > AIPcS4 • Again a 
marked effect of the central ion and degree of sui phonation is observed with the 
Zn series in general showing higher vessel retention than the corresponding AI 
derivatives. The large difference in tissue selectivity between the Al3 + and Zn 2 + 
complexes likely reflects the presence of an axial ligand in the case of the 
AlPeS, which affects aggregation and dye association with macromolecules. 
The increased tumor specificity of the higher sulphonated MPcS, is in 
agreement with earlier studies on radiolabeled gallium sulphophthalocyanines 
(Rousseau et a!., 1990) and contrasts the poor cell uptake properties of these 
hydrophillic dyes in vitro. Under in vitro conditions, particularly the amphiphilic 
di- and monosulphonated derivatives are readily taken up by cells (Berg et a!., 
1989; Paquette et a!., 1988). Therefore, the relationship between the 
lipophilicity of the dye and cell uptake in vitro is the inverse of findings 
concerning tumor uptake in vivo (Chan et a!., 19901 These differences likely 
reflect the dominant role of the extracellular matrix and stroma of the tumor in 
accumulating the hydrophillic negatively charged, higher sulphonated 
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phthalocyanines. Since quantifications of the dyes are based on their 
fluorescencer differences in aggregation and binding to serum components 
between the various dyes (which diminishes fluorescence yields) should be 
taken into account for their potential use as tumor localizers. The presence of 
more than one sulphonated MPcS" species in a given dye preparation further 
affects their tendency to aggregate. Thus our earlier report on the fluorescence 
ratios of ZnPcS2 (van leengoed et a!., 1991 I actually involved a mixture of 
mono- and disulphonated derivatives (ZnPcS,_51 resulting in much higher T/NT 
fluorescence ratios than those observed with the purified mono- and 
disulphonated ZnPcS, and ZnPcS 2 fractions used in the present study (Fig. 21. 
The profiles of the fluorescence kinetics of the blood vessels are similar for the 
dyes chelated with either Zn 2+ or Al3 +, although the overall BV/NT ratios for the 
Zn complexes are substantially higher (Fig. 2). Only two of the dye preparations, 
i.e. the AIPcS4 and AIPcS 2, show higher TiNT than BV/NT ratios, even at 5 min 
p.i. It is possible that changes in fluorescence yields between plasma bound 
dyes and interstitial bound dye accumulated in the tumor, contribute to such 
differences. 
In conclusion our data suggest that phthalocyanines chelated with Al3+ are 
better tumor fluorescence probes than dyes bearing Zn 2+ as the central metal 
ion. Particularly AIPcS4 and AIPcS2 feature the desired in vivo fluorescence 
distribution profile, suitable for tumor imaging and photodynamic therapy. 
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Abstract 
Six sulphonated metallophthalocyanines, chelated with either aluminum or zinc 
and sulphonated to different degree, were studied in vivo for their photodynamic 
activity in a rat skin fold chamber model. The chamber, located on the back of 
female WAG/Rij rats, contained a syngeneic mammary carcinoma implanted into 
a layer of subcutaneous tissue. Twenty four hours after i.v. adminstration of 
2.5 pmol/kg of one of the dyes, the chambers received a treatment light dose of 
600 J/cm2 with monochromatic light of 675 nm at a power density of 
100 mW/cm2 • During light delivery and up to a period of 7 days post treatment, 
vascular effects of tumor and normal tissue were scored. Tumor cell viability 
was determined by histology and by rein plantation of the chamber contents into 
the skin of the same animal, either 2 h post treatment or after the seven day 
observation period. Vascular effects of both tumor and subcutaneous tissue 
were strongest with dyes with the lowest degree of sulphonation and decreased 
with increasing degree of sulphonation. Tumor regrowth did not occur with 
aluminum phthalocyanine mono- and disulphonate and with zinc phthalocyanine 
monosulphonate. With the protocol that was used, complete necrosis without 
recovery was only observed when reinplantation took place at the end of the 
seven day follow-up period. Reinplantation 2 h post treatment always resulted in 
tumor regrowth. At this interval, the presence of viable tumor cells was 
confirmed histologically. In general tumor tissue vasculature was more 
susceptible to photodynamic damage than vasculature of the normal tissue. The 
effect on the circulation of both tumor and normal tissue increased with 
decreasing degree of sulphonation. Based on this study, the photodynamic 
effects using the six sulphonated metallophthalocyanines on the vasculature can 
be ranked from high to low as: AIPcS2 "' ZnPcS, > AlPeS, > AIPcS4 > ZnPcS2 
> ZnPcS4 • 
Introduction 
In photodynamic therapy (PDT) of cancer, light of an appropriate wavelength 
and dose is applied to activate a photosensitive dye, which is retained in (tumor) 
tissue after systemic administration. The degree of retention of the dye in tumor 
tissue, the presence of oxygen and the ability to deliver light in an adequate 
dose determine the chances of a successful therapy with minimal damage to the 
surrounding normal tissue. To date most of the clinical experience in PDT is 
accumulated with hematoporphyrin derivative (HPD) or Photofrin®, a commercial 
preparation enriched in the active fraction of HPD, as the photoactive drug. 
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Although the results are encouraging, the prolonged skin photosensitivity and 
low extinction coefficients at clinically relevant wavelengths are regarded as 
significant drawbacks. 
Because of their high extinction coefficient (E ~ 105 M.1 cm·1) in the red 
region of the spectrum (between 670-680 nm) phthalocyanines (Pel have been 
suggested as "second generation" photosensitizers for PDT (Spikes, 1986). 
They are structurally similar to porphyrins, are relatively stable, are active as 
single products and fluoresce in their active form. These qualities, together with 
their tumor tissue retention, make them ideal for the combination of tumor 
tissue localization by fluorescence and photodynamic tumor therapy (for recent 
reviews see van Lier (1990a) and Rosenthal (1991)). 
Complexing the phthalocyanine molecule with a diamagnetic metal ion such as 
Zn 2 + or Al3 + increases its triplet yield and lifetime. On the other hand, their 
hydrophobicity causes unsubstituted phthalocyanines to aggregate in an 
aqueous solution, diminishing its usefulness for biological applications. Adding 
sulphonate groups to the molecule reduces this tendency and results in a dye 
with suitable photodynamic properties. The number of sulphonate groups 
attached to the phthalocyanine molecule is inversely correlated with its 
hydrophobicity. 
Sulphonated metallophthalocyanines (MPcS.l are effective photosensitizers 
both in vitro (Ben-Hur and Rosenthal, 1986; Brasseur et al., 1987; Berg eta/., 
1989; Peng eta/., 1990) and in vivo (Brasseur eta/., 1987; Tralau eta/., 1987) 
and vascular effects are associated with the photodynamic effects (van 
Leengoed eta/., 1991). However, there is a discrepancy between the localizing 
properties of MPcS. in vivo and in vitro (Chan et a/., 1990) and it has become 
clear that the central metal ion and the ring substituents play a predominant role 
in the photodynamic properties of phthalocyanines. Much of the earlier work on 
phthalocyanines has been done with aluminum phthalocyanine tetrasulphonated 
(AIPcS4 ). However, this commercial preparation is a mixture of molecules with 
different degrees of su!phonation with an average of three. 
In this paper we have compared the photodynamic activity in vivo of six 
phthalocyanines differing in central metal ion and degree of sulphonation. In 
particular the vascular effects of PDT using phthalocyanines are discussed with 
respect to tumor tissue necrosis. 
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Materials and methods 
Photosensitizers 
The six species of sulphonated metallophthalocyanines (MPcS"), differing in their 
central metal ion (AI3+ or Zn 2 +) and degree of sulphonation (mono- di- or tetra-
sulphonate) were prepared via the condensation method as previously described 
(Ali eta/., 1988). Homogeneity of the dye preparation was verified by reversed 
phase HPLC and showed that the disulphonated preparations were enriched in 
isomers with sulphonate groups on adjacent benzo groups. The concentration of 
the dye was determined by optical absorbance measurement in DMF using 
€ = 2.5 x 105 M 1 em 1 at Am~ = 675 nm. 
Cremophor El (Sigma) was added to the mono sulphonated phthalocyanines 
to prevent aggregation and precipitation of the photosensitizer and stock 
solutions of the individual MPcS" were supplemented with phosphate buffered 
saline (PBS) to yield an i.v. injectable solution. 
The dyes were administered in a concentration of 2.5 pmol/kg via a tail vein 
24 h prior to light delivery. 
Animal Model 
Twelve to fourteen week old female WAG/Rij rats were obtained from ITRI-TNO, 
Rijswijk, The Netherlands. The skin fold chamber (Reinhold eta/., 1979; Star et 
a/., 1986; van leengoed eta/., 1990), is a 0.5 mm thick layer of subcutaneous 
tissue of the dorsal skin placed between two transparent covers, one of which 
can be removed to permit the insertion of approximately 1 mm3 of syngeneic 
mammary carcinoma tissue. When placed under a microscope at low 
magnification, the veins, arteries and the capillary beds of subcutis and tumor 
tissue can be observed. 
During the entire experimental procedure the animals were kept in a 
temperature controlled (32°Cl cabinet. The elevated ambient temperature 
ensures adequate tumor growth in the chamber. The ambient light level inside 
the cabinet was reduced to less than 30 pW/cm', providing the animals with a 
day/night cycle without causing observable photosensitization. 
During the preparation procedure, for sedation during therapy and during the 
follow-up procedures, Hypnorm® (fluanisol/fentanyl mixture, Janssen Pharma-
ceutics, Beerse, Belgium) was used as a general anaesthetic. 
Experimental procedure 
Each dye was studied in a group of six animals. Twenty four hours before 
phototherapy the animals received a dose of 2.5 pmol/kg. 
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Light of 675 nm was obtained from an argon-dye laser (Spectra Physics 
system 171), with DCM (4-dicyanometyhlene-2-methyi-6(P-dimethylamino-
stytyi)-4H-pyran) as the lasing dye. Through an optical fibre and a lens system 
with diaphragm, the laser light was delivered through the stage of a microscope 
and directed to the back of the chamber. The circular beam covering the entire 
chamber (1 0 mm diameter), had an incident power density of 100 mW/cm' at 
the surface of the chamber as measured by a Spectra Physics 404 power meter. 
In order to deliver a light dose of 600 J/cm', an illumination period of 100 min. 
was required. 
During PDT and up to 7 days after PDT the damage to the vasculature of 
tumor and normal tissue was rated on a 0-8 scale. A score of 0 corresponds to 
no observable damage whereas a score of 8 means no observable circulation. 
Two hours after PDT one chamber of each experimental group was fixed in 
formaldehyde. The tissue was removed from the chamber, embedded in paraffin, 
cut in 10 pm sections and stained with Haematoxylin-Eosin. At the same two 
hour interval after PDT, the chamber of two animals from each group was 
removed and their content was transplanted into the flank of the same animal. 
In the remaining three animals the vascular damage score was determined daily 
until 7 days post treatment. Then, these chambers were also removed and the 
remainder of the treated tissue transplanted into the flank of the animal. The 
animal was observed for a 100 days for the occurrence of tumor regrowth. 
Results 
At different stages during and after light delivery a number of aspects of 
vascular damage could be distinguished in our model system. A typical sequence 
of vascular effects that will lead to tissue necrosis may start with spasm of the 
arteries in the chamber (Fig. 1 B). This vascular spasm may be followed by 
ischaemia (blanching of the tumor) and a reduction of the red blood cell column 
diameter in the larger venules (Fig. 1 C). The capillaries may become dilated and 
packed with red blood cells. Eventually stasis will occur not only in the 
capillaries, but also in the larger vessels. Extravasation of blood, especially in the 
tumor area, may then also be observed. If these severe vascular effects are 
maintained over a period of more than one day, tissue necrosis occurs. When 
the vascular effects were less, then the larger vessels remained intact and the 
recovery of the capillary bed of the tissue was observed. 
The circulation damage score ranging from 0 to 8 was assessed separately for 
tumor and surrounding normal tissue and shown in fig. 2 A-D. Vascular damage 
was least with MPcS4 , a circulation stop occurred only with AIPcS4 (Fig 28) and 
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Fig. 1. Observation chamber vasculature before (A) and during illumination at 
7 5 min. (8), 60 min (C! and 2 h after the end of treatment (D). The animal was 
sensitized with ZnPcS2 and the chamber received a total light dose of 600 J/cm 2 (1 00 
min. x 100 mW/cm2). Arrows indicate the disappeared artery (b) and the reduced 
diameter of the vein (C). Reperfusion after treatment (D) often results in extravasation 
of blood from the capillaries. 
this is observed only 2 h post treatment. Tumor regrowth was observed in all 
cases when reinplantation was performed either 2 h or 7 days post treatment. 
Stronger vascular effects were observed with MPcS2 where ZnPcS2 as well as 
AIPcS2 caused maximum circulation damage scores both in tumor as in normal 
tissue. In one animal that was injected with ZnPcS2 (Fig 2AL thrombi were 
observed after 60 minutes of light delivery. Two hours post treatment, complete 
stasis in the tumor tissue was observed, but the circulation started to recover 
2 days post treatment. In the normal tissue (Fig. 2C) a complete stop of the 
circulation was never observed and tumor regrowth occurred in all instances like 
with MPcS4 . In chambers treated with AIPcS2 maximum damage scores were 
observed not only in tumor tissue but also in normal tissue and this effect 
persisted during the entire observation period (Fig. 28-0). Tumor regrowth was 
observed only when reimplantation was performed two hours post treatment 
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and not after reinplantation at the end of the 7 day observation period. At this 
interval the tissue had not yet become necrotic. Vessel constriction, especially 
of the arteries, was observed with both dyes, but was most striking with 
ZnPcS 2 where it was observed already at 5 min. after the beginning of the light 
delivery. 
In MPcS,, circulation damage patterns similar to those observed with AlPeS, 
were seen. Here also viable tumor cells were apparently present 2 h post 
treatment but reimplantation after the 7 day observation period did not result in 
tumor regrowth. When comparing the two monosulphonated dyes, vascular 
spasm of the arteries again was most prominent with the Zn 2 + dye. In chambers 
of animals that received ZnPcS1 , thrombi in the venules were observed in four 
animals, already 15 minutes after the start of the light treatment. These thrombi 
usually did not form a permanent obstruction of the blood vessel as reperfusion 
was often observed. Of all dyes studied the vascular effects observed in the 
tumor were always stronger than those observed in the normal tissue. 
Discussion 
Vascular effects 
The mechanism of phthalocyanine induced PDT damage, in terms of vascular 
damage leading to tumor cell death, as a result of hypoxia and nutritional 
deficiency, is comparable with damage patterns observed during HPD-PDT (Star 
et a!., 1986). The vascular effects observed range from a small reduction of 
blood flow with full recovery, to complete stasis sometimes followed by (partial) 
reperfusion with extravasation of blood from the capillary bed, leading to 
necrosis of the entire treated area. Stasis can occur due to swelling of 
erythrocytes in the capillaries or thrombus formation and as a result of 
endothelial damage (Ben-Hur et at., 1990; Ben-Hur et a!., 1988), resulting in 
vascular occlusion (Star et a/., 1986; Reed eta!., 1988). Both phenomena have 
been observed during these experiments. 
Focal or total vasoconstriction can be the result of nervous stimulation and 
could easily be mistaken for thrombi formation along the vessel wall. Edema in 
the chamber could also lead to compression of vessels, resulting in a similar 
reduction of the red blood cell column diameter. Although this could be 
considered an artefact, the reperfusion that is often observed after treatment 
indicates that edema itself cannot be the only explanation of a reduction in 
diameter of the red blood cell column. Furthermore, increased interstitia! 
pressure as a result of an increase of vascular permeability e.g. due to 
inflammation, is a naturally occurring phenomenon in tissue. 
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Fig. 2. Circulation damage scores of tumor tissue f2A-BJ and normal tissue (2C-DJ for 
the six different dyes in this study during and after a treatment light dose of 600 J/cnl 
{100 x 100 mW/cm2) 24 h after administration. The values are group averages of 6 
animals until 2 h and 3 animals for the remaining time. The damage scores range from 0 
(no observable damage} to 8 (no observable circulation). The duration of illumination is 
expressed in minutes. 
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Photosensitizer qualities 
Photodynamic therapy using the experimental parameters in this study resulted 
in sufficient vascular damage to induce full necrosis of both tumor and normal 
tissue in the chamber when the monosulphonated Pc's or AIPcS2 were used as 
photosensitizer. The lack of recovery of the circulation from the damage caused 
by the treatment, separates the effects of these three dyes from both 
tetrasulphonated Pc's and ZnPcS 2 • These observations agree with what has 
been found for PDT effects both in vitro and in viva by others (Paquette eta/., 
1988; Brasseur eta/., 1988; Berget a/., 1989; Peng eta!., 1990). In vivo the 
fluorescence localization of Pc's for tumor tissue is inversely related to the 
degree of sulphonation (Chan et a!., 1990), and was confirmed by our own 
pharmacokinetics study (van Leengoed eta/., 1992). 
Tumor, as well as normal tissue vessel damage generated by the six dyes in 
this study can be ranked from high to low as: AIPcS2 "' ZnPcS, > AlPeS, > 
AIPcS4 > ZnPcS2 > ZnPcS4 • Although the vascular effects in the tumor vessels 
were more predominant than in normal tissue, and extravasation was mostly 
seen in the tumor area, these effects differed only quantitatively from the normal 
tissue vascular effects. lt is important to note that tumor tissue contains only 
capillaries, whereas the surrounding normal tissue also includes larger vessels 
which are less sensitive to PDT damage than capillaries. 
Differences in direct killing of tumor cells between the different dyes could not 
be determined in this in vivo model. The reimplantation assay only revealed the 
presence of sufficient viable tumor cells to give rise to tumor growth, a method 
not very sensitive to the number of surviving cells. Moreover histology at two 
hours post treatment was not conclusive in predicting the success of the 
treatment. Perhaps the interval between the end of the treatment and histology 
should be increased in order to reveal the cellular and vascular effects leading to 
success or failure of the treatment. On the other hand both tests revealed that 
viable tumor cells were present two hours after treatment, for all dyes tested, 
stressing the importance of the indirect effects in PDT with these dyes. 
Light dose 
A total light dose of 600 J/cm' is rather high and seems impractical in a clinical 
setting. In the same chamber model, in order to achieve a similar 100 % tumor 
necrosis using HPD 115 mg/kg), a light dose of 160 J/cm' (630 nm) was 
required (Star et a!., 1986). Practically tumor necrosis was equivalent to total 
necrosis of the chamber. 
A number of aspects should be taken into consideration with respect to the 
high light dose that was needed. In the present study the light dose was chosen 
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high enough to evoke a vascular response even in the higher sulphonated, less 
photodynamically active Pc's. The sensitizer dose used was relatively low 
compared to other studies where it varies between 0.2 to 25 mg/kg and with 
5 mg/kg as the dose most commonly used drug dose. In spontaneous tumors, 
complete responses have been reported with Pc using a drug dose of 1 mg/kg 
and a total light dose of 50-100 J/cm' in various animals and a variety of 
tumors (Roberts eta!., 1991 ). Our drug dose was chosen to accommodate the 
study of the fluorescence pharmacokinetics of these dyes, the results of which 
will be published in a separate paper (van leengoed et a!., 1992). Both 
monosulphonated Pc's and AIPcS2 will probably also be effective at a much 
lower light dose as they showed maximum damage scores at 600 J/cm2 • At a 
low photosensitizer dose photobleaching might become a critical factor. Possibly 
a sixfold increase of the sensitizer dose to 15 pM/kg, to match the dose of HPD 
described above, probably can lead to a reduction of the treatment light dose by 
more than a factor of six (less than 100 J/cm'). 
Light source 
Using a laser to deliver the treatment light might be another source of variation. 
In a wavelength range of 670-680 nm, the Pc's have a narrow absorption band. 
A small shift of this band in a biological environment could result in a dramatic 
decrease of the light absorption at the wavelength the laser is emitting. 
Therefore in order to deliver light at the proper wavelength, the in vivo 
absorbance of the Pc' s is of vital importance. This information is lacking at 
present. A study of the in vivo action spectrum of HPD-PDT has shown that a 
shift of 5 nm can considerably reduce the biological effectiveness of PDT 
(Kessel, 1982). Exciting with a broader wavelength band using a lamp with 
filters as a light source is much less efficient than laser light. On the other hand 
when using the broader excitation band, one may still cover the absorbtion 
maximum of the dye despite possible shifting. 
In conclusion, we have shown that in vivo PDT effects on the vasculature 
increase with decreasing degree of sulphonation of MPcS". Al-based 
phthalocyanines caused more vascular damage leading to tumor necrosis than 
Zn-based phthalocyanines and were also more effective in causing tumor 
necrosis. Our experiments confirm the importance of vascular damage in the 
PDT effects of Phthalocyanines. By comparing the role of the central metal ion 
and degree of sulphonation, AIPcS2 emerges as the MPcS", best suited for 
photodynamic therapy. From fluorescence pharmacokinetics studies performed 
on the same MPcS", AIPcS2 also emerged as a good tumor localizer making the 
dye an interesting candidate for further study. 
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Abstract 
Zinc(JI)-phthalocyanine, a hydrophobic photosensitizer dye, was incorporated in 
unilamellar liposomes and studied in vivo for fluorescence kinetics and 
photodynamic activity. An observation chamber mounted in a dorsal skin fold of 
female WAG/RIJ rats was used as a model system. In the chamber, an isogeneic 
mammary carcinoma was transplanted in the subcutaneous tissue. 
Phthalocyanine fluorescence was excited at 610 nm with a power density of 
0.25 mW/cm2 and was detected above 665 nm through a high pass filter using 
a two stage image intensifier coupled to a CCD camera. Following i.v. 
administration of 0.14 mg/kg of the drug, the fluorescence pharmacokinetics of 
the dye in vasculature, normal tissue and tumor tissue was determined as a 
function of time. After injection, tumor fluorescence increased slowly to a 
maximum about 3 h post injection, and remained well above the normal tissue 
fluorescence till 24 h post injection. Fluorescence in the circulation was always 
stronger than in the tissues. A treatment light dose at a wavelength of 675 nm 
was delivered 24 h p.i .. One group of 6 animals received a total light dose of 
150 J/cm2 (100 mW/cm2 ). A second group of 6 animals received a total light 
dose of 450 J/cm2 at the same dose rate. Vascular damage resulting from 
treatment was observed only at the final stages of the irradiation, despite the 
relatively high levels of fluorescence in the circulation. Immediate post treatment 
(re)transplantation of the content of the chamber into the flank always resulted 
in tumor regrowth, confirming the presence of viable tumor cells following PDT. 
When the chamber was left intact, the light dose of 450 J/cm2 yielded complete 
tissue necrosis. 
introduction 
In photodynamic therapy (PDT) the goal is to achieve tumor necrosis with 
minimal damage to normal tissue using local activation by light of a 
photosensitizer that is retained in the target tissue. PDT is currently undergoing 
clinical evaluation with Photofrin° as photosensitizer, a preparation obtained 
from hematoporphyrin derivative {HPD) and enriched in the active fraction. At 
the same time phthalocyanines are being investigated as alternative 
photosensitizers for PDT (Ben-Hur and Rosenthal, 1986). They are structurally 
similar to porphyrins but in contrast have a high extinction coefficient in the 
670-690 nm range. At this wavelength tissue penetration of light is deeper than 
at 630 nm where porphyrins are excited. 
In vivo fluorescence and PDT using liposome bound ZnPc 49 
Phthalocyanines have a strong tendency to aggregate which renders them 
unsuitable for systemic administration. Adding sulphonic acid groups to the 
molecule (Brasseur et a!., 1987; Tralau et a!., 1987) however yields 
photodynamically active, water soluble derivatives. Their synthesis is relatively 
easy. The subsequent purification on the other hand can be quite elaborate. 
Cutaneous photosensitivity resulting from phthalocyanine administration is 
reported to be much less than from Photofrin® (Tralau eta!., 1989). The dye is 
stable in a biological environment and shows fluorescence in its monomeric, 
active form. Its fluorescence can therefore be exploited for tumor localizing 
purposes, but contrary to photofrin®, also gives information on !oca! dye 
concentration (MacRobert et a/., 1989). Phthalocyanines have been shown to 
photosensitize malignant cells both in vitro and in vivo (for a recent review see 
Rosenthal (1991) and van lier (1990)). 
Tumor localization of the sulphonated phthalocyanines is greatly influenced by 
the lipophilic nature of the drug. From work of others (Chan eta/., 1990) and 
also by our own observations it has been shown that fluorescence based tumor 
localization of sulphonated phthalocyanines is positively correlated with the 
degree of sulphonation of the phthalocyanine molecule (van Leengoed et a!., 
1992). However when photodynamic activity with respect to tumor necrosis is 
concerned, the degree of sulphonation is inversely related to the effect, 
favouring lipophilic dyes over hydrophillic dyes (Brasseur et a!., 1988; Berg et 
a/., 1989). Instead of adding sulphonate groups to the molecule to increase the 
water solubility, liposomes can be used as a carrier system making the lipophilic 
drugs suitable for biological application. In vivo, liposomes associate with the 
lipid core of lipoproteins. Especially low density lipoproteins (LDL) have a high 
affinity for tumor cells through a receptor mediated transport mechanism 
(Goldstein et a!., 1979). liposomes have been shown to facilitate efficient 
targeting in vivo by water insoluble porphyrins (Jori et a/., 1983) as well as by 
Zn(ll)phthalocyanine (Zn(II)Pc) (Reddi eta/., 1987) at very low dosages. 
In this paper, we describe the in vivo fluorescence kinetics of this drug-carrier 
complex and determine the in vivo effects of subsequent optical irradiation on 
tumor necrosis using a dorsal skin fold chamber model. The role of the vascular 
effects resulting from treatment and quenching of photoproducts by the carrier 
complex of the photosensitizer present in the circulation, will be discussed. 
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Materials and Methods 
Animal model 
Female Wag/Rij rats (ITRI-TNO, Rijswijk, The Netherlands) 12-14 weeks of age 
were used. During a three week preparation period the animals were equipped 
with a skin fold chamber on their backs. The chamber includes a 0.5 mm layer 
of subcutaneous tissue, wedged between two transparent covers. Into the 
subcutaneous tissue of the chamber an isogeneic mammary carcinoma was 
transplanted. The animal model permits observation of the pharmacokinetics of 
photosensitizers based on fluorescence and the assessment of vascular effects 
resulting from photodynamic therapy (Star et a!., 1986; van Leengoed et a/., 
1990). Hypnorm® (Janssen Pharmaceuticals, Beerse, Belgium) was used as a 
general anaesthetic during all procedures. In accordance with the Dutch law on 
animal experiments, the protocol was submitted to and approved by the animal 
experiments committee. 
Drug-carrier system 
Zn(ll) Phthalocyanine 
unilamellar liposomes 
(Ciba-Geigy, Basel, Switzerland) incorporated into 
was prepared as previously described (Valduga et a!., 
1987). Briefly, a small volume of a mixture of Zn(II)Pc dissolved in pyridine 
(Janssen pharmaceuticals, Beerse, Belgium) and dipalmitoylphosphatidylcholine 
(DPPC) dissolved in ethanol was slowly injected into saline of 55° C using a 
microsyringe. The suspension was dialysed for 3 h against two times 500 ml 
saline to remove pyridine. The resulting dye concentration was measured by 
optical absorbance using a Lambda 5 (Perkin Elmer) spectrophotometer 
(£;2.41x105 M·' em·' at ..lm~l- A calculated volume of the liposome suspension 
supplemented with phosphate buffered saline (PBS) was administered via a tail 
vein of the animals resulting in a dye concentration of 0.14 mg/kg rat. 
Fluorescence detection 
Fluorescence was excited at 610 nm with a fluence rate of 0.25 mW/cm2 and 
detected above 665 nm using an intensified CCD-camera. Digitized fluorescence 
images obtained from the fluorescence detection system were used to measure 
average grey scale values of selected areas of interest of blood vessel, tumor 
and normal tissue. To minimize individual differences these values were used to 
express fluorescence of tumor tissue and blood vessels as averaged ratios 
relative to normal tissue (subcutis) values. 
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Experimental procedure 
In order to establish the optimum dose for fluorescence detection and PDT, the 
first series of experiments was performed in a pilot study on 14 animals, varying 
drug dose, light dose and interval between drug administration and treatment. 
All experiments began when the tumors in the chambers had reached a diameter 
of 2-3 mm. Two drug doses were compared: 0.14 mglkg and 0.21 mglkg. The 
animals were anaesthetized and following the recording of an autofluorescence 
image the dye-carrier complex was administered via a tai! vein of the animal. At 
5 minutes and at 24 h p.i., fluorescence images were recorded. 
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Fig. 1. Absorbtion spectrum of zinc-phthalocyanine in pyridine. The two excitation 
wavelengths used in this study, 610 and 675 nm, are indicated by arrows. 
Twenty four hours after dye administration, a treatment light dose of 450 or 
900 Jlcm' was delivered to the chamber, using an irradiance of 100 mWicm' at 
610 nm, obtained from an argon ion pumped dye laser system (Spectra Physics 
171 + 375). The wavelength of 610 nm is at the fluorescence excitation 
maximum closest to the fluorescence emission wavelength of 675 nm (Fig. 1 ). 
In this pilot study Rhodamine was used as the lasing dye because 
fluorescence was the primary objective. With Rhodamine it is not possible to 
generate light of 675 nm, the wavelength at which ZnPc has maximum light 
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absorbtion. Therefore, when it was later decided to include PDT, this was 
performed at 610 nm. In the subsequent series of experiments DCM 
(4-dicyanometyhlene-2-methyi-6(P-dimethylaminostytyi)-4H-pyran) was used as 
the lasing dye, because it allows generation of both 610 and 675 nm light (see 
below). 
After treatment the vascular effects were scored for a period of 7 days using 
a microscope at low magnification. After the observation period the content of 
the chamber was transplanted subcutaneously into the flank of the same animal 
to obtain a estimate of tumor cell viability. 
All subsequent series of experiments were performed using a drug dose of 
0.14 mg/kg (see discussion). In a group of 6 animals, fluorescence 
pharmacokinetics was observed at 5, 15, 30, 60, 120, 180 240, 300, 360 min. 
and at 24 h p.i. respectively. Each digitized image was accompanied by a similar 
image of a piece of reference material (coloured plastic). This enabled correcting 
the fluorescence image for inhomogenities in the detection system optics and 
variations in laser output. Twenty four hours p.i. a treatment light dose of 
150 J/cm' (1 00 mW/cm', 675 nm) was delivered to the chamber. During and 
after treatment, vascular effects of tumor and normal tissue were scored on a 
0 to 8 scale. A score of 0 corresponds to no observable effect on the 
vasculature whereas a score of 8 indicates no circulation. Two hours after 
treatment one chamber was prepared for histology and from two animals the 
content of the chamber was transplanted into the flank of the same animal. In 
the remaining three animals transplantation was performed at the end of a seven 
day follow-up period during which the vascular damage was assessed daily. In 
order to achieve tumor necrosis, in a third group of six animals .. the therapeutic 
light dose was increased to 450 J/cm'. 
Results 
In the pilot experiments, both fluorescence excitation and photodynamic therapy 
were performed using light of 610 nm (see Materials and Methods). The results 
of these experiments are summarized in Table 1. 
Tumor fluorescence (c) showed little selectivity with 0.21 mg/kg and 
exceeded the background in only 3 out of 10 animals. Complete necrosis (f) was 
observed at both light dosages using a drug dose of 0.21 mg/kg. A light dose of 
900 J/cm' was required when a drug dose of 0.14 mg/kg was used. When 
retransplantation took place immediately following therapy, tumor regrowth was 
observed with both drug doses. 
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Figure 2 shows digital fluorescence images of liposome bound phthalocyanine in 
the chamber model before and at 4 different intervals after i.v. administration of 
0.14 mg/kg. Note that the fluorescence of tumor and blood vessel increases 
following administration and that even at 24 h both tumor and blood vessels 
fluorescence exceed that of the normal tissue. 
Table 1. Results of the pilot experiment comparing: drug dose {a), treatment interval {d) 
and light dose (e) with the results of tumor fluorescence (c) and treatment effect 
specifically with respect to complete necrosis of tumor and normal tissue {f) as well as 
tumor regrowth (g) for a total of 14 animals (b). Treatment light of 610 nm wavelength 
was delivered to the chamber at an irradiance of 100 m W/cm 2• 
Zn-Pc No. Flu Interval light Complete Regrowth 
(mglkg) 24 h p.i. h (J/cm2 ) Necrosis 
a b 
' 
d • f g 
2 24 450 2 
0,14 4/4 
2 24 900 
2 + 2 24 & 48 450 1 + 1 2 
0,21 3/10 
4+2 24 &48 900 1 + 1 4 
-
14 5 + 9 
The fluorescence signals of tumor, blood vessel and normal tissue following 
i.v. administration of the drug are expressed as averaged grey scale values in 
Fig. 3. After the dye has been administered, fluorescence in the blood vessels 
increases slowly, reaching a plateau at 120 min. p.i. Then, the fluorescence 
signal remains stable but the ratio starts to decline (Fig. 4), due to the slow 
increase of fluorescence in the normal tissue. Tumor tissue versus normal tissue 
ratios increase even more slowly, reaching a maximum value approximately 5 h 
p.i. Two hours p.i. a ratio of two is exceeded and this level is maintained over a 
three hour period between 2 and 5 h p.i. Interestingly, at 24 h p.i., the 
fluorescence in both the tumor and the circulation exceed that of the normal 
tissue. 
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Twenty four hours p.i., a treatment light dose of 150 J/cm' (100 mW/cm', 
675 nm) was administered to the chamber. This light dose was based on a ratio 
of about 6 between the optical absorbtion of ZnPc at 675 and 610 nm (see also 
discussion). With this light dose complete necrosis was never observed. 
Retransplantation, either two hours after treatment or at the end of the 
observation period, consistently resulted in tumor regrowth. The presence of 
vital tumor cells was confirmed by histology. 
Fig. 2. Digitized fluorescence images of ZnPc-lip taken before {center), 5 {A), 60 {8), 
360 min. (C) and at 24 h p.i. {D). Note the tumor fluorescence at 360 min and the 
persistence of fluorescence in the circulation. In terms of average grey scale values, 
f/uorescecne of the tumor still exceeds values of the normal tissues at 24 h p.i. 
In order to achieve tumor necrosis it was decided to increase the dose to 
450 J/cm'and the averaged circulation damage scores of the third group of 6 
animals are shown in Fig. 5. Using this light dose, maximum damage scores 
were observed in tumor tissue starting with day one. A small recovery of the 
circulation in the normal tissue of one animal resulted in the drop of the average 
damage score below 8 but the damage score in tumor tissue remained maximal 
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during the observation period. Complete necrosis without recovery was 
observed in all three cases that were monitored during the whole observation 
period. When the content of the chamber was retransplanted 2 h after treatment 
regrowth was observed. Histology performed at the same interval again 
demonstrated the presence of vital tumor cells. During treatment the vascular 
effects appeared minimal, increasing only during the last 15 min. of the total 
treatment time of 75 min. 
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Fig. 3. Fluorescence pharmacokinetics of ZnPc-lip following i.v. administration of 0.14 
mg/kg of the drug-carrier complex. Fluorescence was measured as grey scale values 
and averaged over 6 animals. 
Discussion 
Hydrophobic photosensitizers like ZnPc, which have excellent photochemical and 
photophysical properties for PDT, but will aggregate in an aqueous environment, 
can be incorporated into liposomes and administered systemically. In this way 
about 30 % of liposome bound photosensitizers can be selectively transferred to 
LDL {Jori, 1989). These lipoproteins can be endocytosed by neoplastic cells 
through a specific receptor mediated pathway. Several malignant tissues have 
an elevated numbers of LDL receptors {Spikes and Jeri, 1987). A large amount 
of drug can thus be accumulated by the tumor tissue in spite of the low injected 
doses {Reddi eta!., 1987). 
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During the pilot experiment, laser light of 675 nm was not available. The 
photosensitizer was therefore excited at 610 nm, a local maximum in the 
absorbtion spectrum (Fig. 1 ). This wavelength was also used for fluorescence 
excitation. Based on the results of this pilot study a sensitizer dose of 
0.14 mg/kg was selected as optimal to study both fluorescence 
pharmacokinetics and photodynamic effects of the drug-carrier complex. 
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Fig. 4. Averaged ratios :1:: SEM of tumor tissue fluorescence and blood vessel 
fluorescence relative to normal tissue (subcutis) fluorescence following dye 
administration 10.14 mg/kg). 
Although a larger photosensitizer dose was expected to result in increased 
phototoxicity, the increase in normal tissue fluorescence using 0.21 mg/kg had 
an adverse effect on the tumor over normal tissue fluorescence ratio. This was 
caused by the increased fluorescence in the normal tissue. The sensitizer dose 
of 0.14 mg/kg in combination with treatment light of 610 nm and a total light 
dose of 900 J/cm2 was sufficient to cause tumor necrosis. This light dose was 
rather high but should be viewed with regard to the low extinction coefficient of 
ZnPc at this wavelength (see below for 675 nm). 
Phthalocyanine fluorescence can be employed as a diagnostic tool to monitor 
the presence of the photosensitiser in its monomeric, active state (MacRobert et 
a!., 1989). Detecting HPD or Photofrin® in this way is more complicated because 
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these drugs contain a number of components with different relationships 
between fluorescence and photodynamic activity. 
After administration of the dye-carrier complex, a gradual accumulation of 
fluorescence in the circulation as well as in the tumor (Fig. 3) is observed. 
Interestingly the fluorescence in the circulation reached its peak only 120 min. 
p.i.. When studying sulphonated phthalocyanines in the same chamber model, 
usually a fluorescent angiogram with the highest intensity in the circulation is 
observed immediately p.i., followed by a gradual decrease of the fluorescence in 
time (van Leengoed et a/., 1990). The increase of the fluorescence in the 
circulation till 120 min. p.i. might be explained by considering the self-quenching 
of fluorescence due to the relatively high concentration of the photosensitizer in 
the carrier system. 
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Fig. 5. Circulation damage scores of tumor tissue and normal tissue, during and after a 
treatment light dose of 450 J!cm' (100 mW/cm',675 nm/ 24 h after i.v. administration 
of ZnPc-/ip. Scores range from 0 (no observable damage/ to 8 !no observable 
circulation). Values are averaged over 6 animals and the duration of the treatment is 
expressed in minutes. 
This increase of fluorescence could represent the release process by the carrier 
system of the photosensitizer similar to what has been described for fluorescein 
(Weinstein eta!., 1977). 
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The fluorescence signal in tumor tissue increases even more slowly than the 
fluorescence in the circulation. This observation probably relates to the fact that 
the liposome bound ZnPc is taken up by lipoproteins before being accumulated 
by the tumor cells through an active process. Between 3 and 5 h p.i. the tumor 
fluorescence exceeds a ratio of 2 (Fig. 4) making it well detectable against the 
normal tissue fluorescence which hardly increases during this interval. This 
interval could therefore be utilized for tumor detection. The limited increase of 
fluorescence in the normal tissue also contributes to the fact that at 24 h p.i. 
both tumor and blood vessel fluorescence remain detectable. When tested in the 
same tumor model system at 24 h p.i., HPD and Photofrin® fluorescence usually 
appeared lower in the tumor than in the normal tissue. 
Exciting the photosensitizer at 610 nm with 900 J/cm' resulted in tumor 
necrosis in one out of two animals using a sensitizer dose of 0.14 mg/kg. When 
the sensitizer was excited at 675 nm, a sixfold reduction of the total light dose 
was expected to yield similar results. This idea was based on the fact that 
phthalocyanine absorbtion at 675 nm appeared at least 6 fold larger than at 
610 nm (Fig. 1 ). Actually, one day after treatment the vasculature of the normal 
tissue was already recovering and tumor regrowth was always observed. On the 
other hand tumor necrosis was achieved when a light dose of 450 J/cm' was 
used but this light dose also caused a maximal effect on the normal tissue 
circulation. To explain these observations we propose that ln vivo, aggregation 
of the dye may occur and this will result in a reduction of the actual differences 
in optical absorption. 
A drug dose of 0.14 mg/kg can be considered very low compared to the dose 
of Photofrin® (1 0 mg/kg) or sulphonated phthalocyanines (2.5-5 mg/kg) used in 
experiments with rats. The fact that tumor necrosis was observed with this low 
drug dose suggests that the targeting of the photosensitizer using liposomes as 
carriers is effective. 
Targeting of the photosensitizer towards individual tumor cells is expected to 
result in more direct cell kill (Zhou et a!., 1988). However from our data it 
appears that the number of tumor cells killed directly is not sufficient for tumor 
control. Retransplantation immediately after treatment always resulted in tumor 
regrowth. Moreover, viable tumor cells were confirmed histologically 2 h after 
treatment. Tumor cell kill cannot be quantified using our method. It only allows 
the demonstration of the presence or absence of tumor cells capable of causing 
tumor regrowth. Tumor control by PDT with ZnPc-lip therefore probably requires 
vascular damage in a margin of normal tissue about the tumor. 
During the first 5 min. of illumination, vasospasm of arteries was the most 
striking vascular effect that was observed. This vasospasm usually disappeared 
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within the first 30 min. of irradiation. In comparable experiments using 
sulphonated phthalocyanines similar vasospasm of the arteries was observed. 
These effects were stronger using dyes chelated with zinc as a central metal ion 
compared to aluminum. The vasospasms were considered to cause hypoxia and 
assuming that oxygen is indispensable for Pc-PDT (Bown et a/., 1986) thereby 
negatively influencing the effectiveness of the photochemical reaction. Using 
liposome bound ZnPc it seems that after the initial response of the artery to the 
treatment, arterial blood supply is restored till the end of treatment. During the 
period of illumination no thrombi or vasoconstriction of the larger veins could be 
observed. By the end of the treatment period stasis was observed predominantly 
in the capillary bed of both tumor and surrounding normal tissue. However, 
judging from the initial vasospasms and damage to the capillary bed, the 
endothelium is likely to be a target for PDT using ZnPc-lip. These findings agree 
with what has been found by Milanesi (1987) and Evensen (1983). The vascular 
effects reach their maximum values between 2 h post therapy and day 1 (Fig. 4) 
and cannot be distinguished from the inflammatory response to the treatment. 
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Abstract 
Bacteriochlorin a (BCA), a derivative of bacteriochlorophyll a, is an effective 
photosensitizer in vitro and in vivo. BCA has a major absorption peak at 760 nm 
where tissue penetration is optimal. This property, together with rapid tissue 
clearance promises minor skin photosensitivity. The tissue localizing and 
photodynamic properties of BCA were studied using isogeneic RMA mammary 
tumors, transplanted into subcutaneous tissue in transparent "sandwich" 
observation chambers on the back of WAG/Rij rats. The fluorescence kinetics 
following an i.v. administration of 20 mg/kg BCA was assessed in blood vessels, 
tumor and normal tissue. Subsequently, the development of vascular- and tissue 
damage after a therapeutic light dose (760 nm, 600 J/cm2 ) was observed. 
Fifteen minutes post injection (p.i.), the fluorescence of BCA in the tumor 
reached a plateau value of 2.5 times the fluorescence in the normal tissue. From 
one hour post injection the tumor fluorescence diminished gradually; after 24 h 
the tumor fluorescence signal did not exceed that of the normal tissue. 
Following photodynamic therapy (PDT), 24 h p.i., complete vascular stasis was 
observed 2 h post treatment in the tumor only, with subsequent recovery. The 
presence of viable tumor cells following PDT was assessed by histology and 
retransplantation of treated tumor tissue from the chamber into the flank 
immediately or 7 days after treatment. In both cases tumor regrowth was 
observed. BCA-PDT (20 mg/kg, 760 nm, 100 J/cm2 ) one hour after BCA 
administration, an interval which gives the optimal differential between tumor 
and normal tissue, was sufficient to prevent tumor regrowth. However, this only 
occurred when re-transplantation was performed 7 days after PDT. During PDT, 
one hour p.i., vascular damage in tumor and normal tissue was considerable. 
Complete vascular shut-down was observed in the tumor 2 h after therapy and 
in the surrounding tissues at 24 h. Circulation damage was associated with 
vascular spasm and occlusion probably due to thrombi formation. Oedema was 
notable, especially following PDT with 600 J/cm2 at 24 h p.i. 
Introduction 
Tumor destruction by photodynamic therapy is achieved through retention of 
photosensitizing compounds ln tissue after injection and the subsequent 
activation of these compounds by irradiation with light of appropriate 
wavelength and dose. The photosensitizer currently evaluated in phase Ill clinical 
trials is Photofrin®, a derivative of hematoporphyrin, enriched in the 
photodynamically active fraction. However, Photofrin® has a number of 
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drawbacks. In particular it induces skin photosensitivity for periods up to 
6 weeks and is chemically ill defined. These drawbacks have prompted an 
intensive worldwide search for new photosensitizers (Kessel, 1990). A good 
candidate for "second generation" photosensitizer is bacteriochlorin a IBCA). 
BCA is a derivative of bacteriochlorophyll a and a potent photosensitizer both 
in vitro and in vivo (Schuitmaker et at., 1990). Its lipophilic nature enhances the 
cellular uptake of the dye (Richter et at., 1991 ). Effects on mitochondria ex vivo 
resulting from therapy (Schuitmaker et at., 1991) and in vivo tumor fluorescence 
have been demonstrated (Schuitmaker et at., 1992). This photosensitizer has a 
major absorption peak at 760 nm, a wavelength where tissue penetration is 
optimal (Star et at., 1992). With this photosensitizer the penetration depth of 
the therapeutic light and thus the treated volume may be maximized. 
The exact mechanism of tumor necrosis resulting from PDT is still not fully 
elucidated. Originally it was thought that PDT was effective only through the 
selective localization of the photosensitizer in the tumor cells. The tumor cells 
were subsequently killed by singlet oxygen, produced when the dye was 
irradiated with light of an appropriate wavelength. However, there exists 
accumulating evidence that an important and immediate effect of PDT is on the 
vasculature of the tumor and surrounding tissues, depending on the sensitizer 
used (Henderson and Dougherty, 1992). This results in a decreasing blood flow 
and eventually vascular stasis (Star et at., 1986; Franken et at., 1988; 
Schuitmaker et at., 1990). The fluorescence of BCA is of practical interest in 
PDT as it may be a sensitive non-contact way of detecting otherwise occult 
cancers and make them accessible for regular biopsy, eventually combining 
potential tumor tissue identification and photodynamic therapy (lam et at., 
1990). 
In the present paper we report on the fluorescence kinetics of BCA and on 
BCA-PDT induced damage to tumor and normal tissue circulation in vivo. 
Materials and Methods 
Preparation of BCA 
Bacteriochlorophyll a was obtained by extraction from the photosynthetic 
anaerobic bacterium Rhodospirillum rubrum and purified according to the method 
of Ornata et al. (1g83). The purity of the pigment was checked by thin-layer 
chromatography (TLC). Using an eluent of 93% methanol and 7% phosphate 
buffer (pH 7, 10 mM), the bacteriochlorophyll a yielded a single blue spot 
(relative mobility approximately 0.5) on Machery-Nagel Nano-Sil C18-1 00 TLC 
plates (Duren, Germany). Bacteriochlorophyllin a was obtained by saponifying 
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bacteriochlorophyll a as described by Oster et al. (1964). The central magnesium 
ion of bacteriochlorophyllin a was removed with 50 mM sodium acetate 
(pH 4.5), and the BCA formed was then extracted with ethylacetate. 
Ethylacetate was evaporated under reduced pressure, and BCA was lyophilized 
overnight and stored at -20°C in the dark under nitrogen. Throughout the 
extraction and modification procedures care was taken to work under reduced 
light and at 4°C as much as possible. 
For intravenous administration lyophilized BCA was dissolved in 3 ml 
methanol; 0.15 ml propane-1 :2-diol (BDH, England) and 0.5 ml Cremophor EL 
(Sigma, St. Louis, USA) were added and the mixture was shaken vigorously. 
Thereafter the methanol was evaporated under reduced pressure and finally the 
mixture was diluted with sterile 0.9% NaCI to yield an i.v. injectable suspension 
with a suitable BCA concentration of 20 mg/kg. For each experiment the 
suspension was freshly prepared and used within 2 hours. 
Animal Model 
Female WAG/Rij rats 12-14 weeks of age (ITRI-TNO, Rijswijk, The Netherlands) 
were equipped with a transparent observation chamber (Reinhold eta!., 1979) in 
a dorsal skin flap. At the end of a three week preparation period, approximately 
1 mm3 of an isogeneic mammary tumor was transplanted into the subcutaneous 
tissue in the chamber. This in vivo model enables monitoring of fluorescence 
kinetics in blood vessels, tumor and subcutaneous (normal) tissue of the 
chamber following i.v. administration of a fluorescent dye (van Leengoed eta/., 
1990). It is also possible to observe the development and recovery of vascular 
damage in tumor and normal tissue after a therapeutic light dose. Through all 
procedural steps Hypnorm® (fluanisol/fentanyl mixture, Janssen Pharmaceuticals, 
Beerse, Belgium) was used as an anaesthetic. 
Fluorescence Localization 
BCA fluorescence was excited at 514.5 nm using an argon-ion laser (Spectra 
Physics model 171) at the very low power density of 0.1 mW/cm2 , in order to 
avoid tissue damage caused by photoactivation of the dye. BCA fluorescence 
was detected through an RG 665 nm high pass filter using an imaging system 
capable of detecting very low light levels. The resulting digitized images were 
subject to image analysis yielding average grey scale values per time interval of 
selected areas of interest in tumor tissue, normal tissue and a blood vessel. 
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Photodynamic therapy 
Light of 760 nm wavelength was obtained from a dye laser (Spectra Physics 
375B, with Styryl 8), pumped by an argon-ion (Spectra Physics 171 I laser. 
Light, at a power density of 100 mWicm2 , was delivered to the chamber via an 
optical fibre and a lens system with diaphragm yielding a uniform beam of 
10 mm diameter covering the entire window of the chamber (1 0 mm in 
diameter). Two groups of six animals were treated. In the first group 
fluorescence was studied and PDT was performed 24 h p.i. of BCA, with a light 
dose of 600 Jlcm 2 • In the second group PDT was performed 1 h p.i. with a light 
dose of 1 00 Jlcm2 • 
Experimental procedure 
The experiments were performed on well vascularized chambers and with vital 
tumors of approximately 3 mm diameter. The animals were immobilized by 
sedation and placed on a temperature controlled positioning stage (30°C) that 
enabled positioning of the chamber under the camera. Before i.v. administration 
of the dye, during the observation period of 2 h and at 24 h p.i., fluorescence 
recordings were made. Each fluorescence recording was accompanied by an 
image of a piece of reference material that fitted on top of the chamber. In this 
way all images could be matched against the reference, enabling correction for 
any fluctuations in excitation light intensity or spatial variations in the sensitivity 
of the imaging system. 
At 24 h p.i. the chambers received a therapeutic light dose. Before, during and 
after the irradiation, the status of the circulation was determined under a 
microscope and scored on a scale from 0 (no observable damage) to 8 (no 
observable circulation). Tumor and surrounding normal tissue were scored 
separately. The status of the circulation of three animals from the group of six 
was determined during a seven day follow-up period. Then, the tumor and a 
margin of normal tissue (or the necrotic remains) was removed from the 
chamber and retransplanted into the flank of the same animal. In two animals 
from each group the tumor and a margin of normal tissue was retransplanted 
2 h after therapy to see whether enough damage was inflicted to prevent tumor 
regrowth. Finally one chamber from each group was prepared tor histology. In 
the second series of six animals a therapeutic light dose of 100 Jlcm2 was 
delivered at a much shorter interval of 60 min. p.i. Apart from that, a similar 
protocol was followed. All sensitised animals were kept under reduced light 
conditions (<30 pWicm2 ) with a 12/12 h day/night cycle. 
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Results 
Digitized fluorescence images of BCA in vivo in an observation chamber are 
shown in Fig. 1. A fluorescence angiogram develops following i.v. administration 
of BCA. The fluorescence in the blood vessels decreases after 5 min. p.i. 
whereas the fluorescence in the tumor increases up to 30 min. p.i. Twenty four 
hours after the administration tumor tissue and blood vessel are 
undistinguishable from the normal tissue. 
Fig. 1. Digital images of the chamber model (inner diameter of 10 mmJ~ showing the 
fluorescence of BCA in tumor, blood vessels and normal tissue at 5 (A), 30 (8), 120 
min. (CJ and at 24 h p.i. fD). Tumor diameter approximately 3 mm. Note the rapid 
clearance from the circulation and the distinct fluorescence of the tumor. Scale: white 
bar represents 2 mm. 
Also at this interval no signs of vascular or tissue damage could be observed. 
Therefore the effects of BCA alone and the excitation of fluorescence were 
considered negligible. 
Figure 2 summarizes the results of the f[uorescence pharmacokinetics study. 
Grey sca[e values measured in selected areas of tumor, blood vessel and normal 
tissue are presented as a function of time following administration of BCA. 
Following administration, the fluorescence in the blood vessels decreases 
whereas tumor fluorescence remains at a constant level until 60 min. p.i. and 
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then starts to decrease. Note that the fluorescence of the normal tissue hardly 
changes during the observation period. When expressed as ratios relative to 
normal tissue, tumor tissue fluorescence increases to a value of 2.5 (interval of 
15 min.). This level is maintained up to 60 min. p.i., but at 120 min. it has 
declined to a ratio of 1.6. At 24 h p.i., the tumor fluorescence ratio has dropped 
below 1. On average, the fluorescence of the normal tissue then slightly 
exceeds that of tumor and vasculature. Blood vessel ratios peak immediately 
post injection and at 5 min. p.i. a level of 2.5 times the fluorescence of the 
normal tissue is recorded. Gradually this level decreases to become 
indistinguishable from the normal tissue (a ratio of 1 l 2 h p.i. 
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Fig. 2. Fluorescence signal measured as average grey scale values of selected areas of 
interest of tumor, blood vessel and normal tissue as a function of time folio wing i. v. 
administration of BCA. The bars represent group averages ± SEM of 6, 6, 6, 5, 3 and 5 
animals respectively. 
The circulation damage scores during and after a therapeutic treatment with 
600 J/cm2 at 24 h p.i. are shown in Fig. 3A. Tumor vasculature appears to be 
damaged to a larger extent than blood vessels in the normal tissue. Only at 2 h 
after therapy a maximum score of 8 (no circulation observed) is reached for the 
tumor vasculature. Figure 3A. also shows that, following the protocol with a 
24 h interval, the circulation in tumor and normal tissue recovers to a score of 
about 3-4 within 6-7 days. Usually the larger vessels recover or existing smaller 
branches increase in diameter. The damaged capillary bed is replaced by new 
capillaries. Note that during the 100 min. of illumination, vascular damage 
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Fig. 3. Circulation damage scores of tumor tissue and normal tissue for the interval 
between administration of BCA and therapy of 24 h and 600 J/cm2 (a) and 1 h and 100 
J/cm2 (b) respectively. The values are group averages of 6 animals until day 0 and 3 
animals for the rest of the experiment. The damage scores range from 0 (no observable 
damage} to 8 {no observable circulation). PDT (abscissa) marks the duration of 
illumination which is expressed in minutes. The observations at day 0 were taken 2 h 
post therapy. Error margins are indicated for two representative observation periods. 
When a mean score of 8 (maximum) is reported, the error is zero. 
In vivo fluorescence and PDT of bacteriochlorin a 69 
developed very slowly reaching a circulation damage score of 3(normal tissue)-
5(tumor tissue) at the end of this period. Histology performed 2 h after the 
treatment light dose demonstrated the presence of viable tumor cells. With this 
treatment regime, tumor regrowth after reimplantation following therapy was 
never prevented, not immediately post treatment nor after the 7 day follow up 
period. 
In the second series of PDT treatments an interval of 1 h between i.v. 
administration of BCA and therapeutic illumination was chosen. This decision 
was based on the results of the fluorescence kinetics study (Fig. 2). Furthermore 
the light dose was reduced from 600 J/cm' to 100 J/cm' in view of the higher 
photosensitizer concentration present at this interval. The vascular damage 
scores of these experiments are presented in Fig. 38. Complete vascular 
shutdown was observed in the tumor 2 h after therapy, similar to the effects 
seen following therapy at 24 h p.i. After 24 h post therapy, the normal tissue 
had no observable circulation either. The vascular effects were already evident 
after 5 min. of illumination resulting in an ischemic tumorr vascular spasm of the 
arterioles as well as venules of the normal tissue. Occlusions in the large vessels 
during and shortly after therapy were possibly caused by the many thrombi that 
were observed. At the end of the therapeutic irradiation there was still some 
circulation present in the normal tissue {damage score of 4). Immediate post-
treatment retransplantation resulted in tumor regrowth for both treatment 
regimes. Viability of tumor cells at this interval was again confirmed by 
histology. Damage scores of tumor and normal tissue remained maximal during 
the 7 day follow up and retransplantation at this interval did not result in 
regrowth of the tumor. 
Discussion 
Depending on the time between i.v. administration of the dye and PDT and on 
the applied light-dose, BCA-PDT eventually resulted in complete vascular stasis 
and prevention of tumor tissue regrowth upon reimplantation at the end of a 
7 day follow-up period. 
In the case of PDT using hematoporphyrin derivative (HPD) or Photofrin® the 
most common interval between administration of the photosensitizer and 
illumination of the tumor is 24-48 h. In a first attempt to realize a therapeutic 
protocol, an interval of 24 h between i.v. administration of BCA and the 
therapeutic illumination was chosen. Furthermore a BCA dose of 20 mg/kg was 
selected based on previous experience (Schuitmaker eta!., 1990). However, as 
Fig. 3A demonstrates, using this protocol and despite the relatively high light 
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dose that was applied, it was not possible to achieve complete and irreversible 
vascular stasis in the observation chamber model and tumor regrowth always 
occurred. This observation coincides with the lack of selectivity and reduced 
fluorescence at 24 h p.i. (Fig. 2). 
Table !. Ratios ± SEM of tumor tissue and vessel fluorescence relative to the 
fluorescence of the normal tissue for different time intervals following administration of 
BCA. 
Time after BCA Ratios± SEM 
administration Tumor Vessel 
5 min. 1.9 ± 0.3 2.5 ± 0.5 
15 min. 2.5 ± 0.5 2.4 ± 0.5 
30 min. 2.5 ± 0.4 2.2 ± 0.5 
60 min. 2.4 ± 0.4 1.8 ± 0.5 
120 min. 1.6 ± 0.2 1.0 ± 0.3 
24 h 0.5 ± 0.2 0.8 ± 0.1 
Therefore, in the second series of experiments the tumor was treated one 
hour after administration of the dye. The choice for this one-hour interval was 
entirely based on the preceding in vivo fluorescence kinetics study (see Table 1). 
This study showed that in the window chamber model, tumor selectivity up to 
2.5 times the fluorescence signal of the normal tissue can be achieved, during 
15 to 60 min. p.i. At 60 minutes p.i. the fluorescence signal ratio of the vessels 
has decreased by approximately 40% of the highest value whereas this ratio in 
the tumor had dropped by less than 5% of its highest value. At twenty four 
hours p.i. tumor and blood vessel ratios become indistinguishable from the 
normal tissue, similar to what is observed with HPD in the same model (van 
Leengoed eta!., 1990). 
A six fold reduction of the light dose to 100 J/cm' (100 mW/cm') was chosen 
as a higher overall concentration of the photosensitizer was expected. This light 
dose resulted in complete and irreparable vascular stasis in the observation 
chamber. Furthermore, tumor regrowth was prevented in those cases where the 
tumor was left in situ during the 7-day follow up period and was subsequently 
retransplanted in the flank of the same animal. 
The fact that 24 h appears not to be the optimum interval has also been noted 
for other photosensitizers, e.g. chlorins (Gomer, 1991) and bacteriochlorophyll a 
In vivo fluorescence and PDT of bacteriochlorin a 71 
(Henderson eta!., 1991 ). As is shown above, the fluorescence kinetics in vivo 
can be used to determine a "therapeutic window" i.e. a suitable time interval 
between dye administration and PDT. This is different from HPD-PDT, where in 
this observation chamber model, 2 h p.i., tumor fluorescence could be 
discriminated from normal tissue in only 40-50% of the cases (van Leengoed et 
a!., 1990). In this model complete necrosis required a light dose of 160 J/cm' at 
630 nm applied 24 h p.i. of 15 mg/kg HPD (Star et a/., 1986). Although 
vascular effects are not the primary target of the therapy, the resulting 
sterilization of the tumor bed will prevent nutritional resupply to still viable tumor 
cells through diffusion or angiogenesis (Fingar and Henderson, 1987) thereby 
enhancing the effect of the therapy. 
The circulation damage scores (Fig. 3A) of the PDT treatment at 24 h p.i. 
show a differential effect on the vasculature of the tumor tissue and the normal 
tissue. This might be partly explained by the fact that in this model, tumor tissue 
only contains capillaries whereas the normal tissue contains capillaries and larger 
vessels. A maximum damage score is reached only 2 h after therapy and only in 
the tumor; from then on the circulation of tumor and normal tissue recovers. As 
a result, PDT treatment 24 h p.i. of BCA rendered no "cures". At this interval no 
fluorescence could be detected in the tumor nor in vessels which in this case 
could indicate that the BCA concentration in the vessels, tumor and normal 
tissue was too low to be effective. When a 24 h interval between administration 
and therapy was studied, the blood supply to the tumor was maintained during 
an illumination time of at least 60 min. (360 J/cm'). This delayed vascular shut 
down might increase the direct tumor cell kill as this is dependent on the 
availability of oxygen. Nevertheless, enough tumor cells apparently escaped 
therapy, causing tumor regrowth in all cases. With only one hour between 
administration and therapy, where BCA fluorescence was still detectable in the 
vasculature, 30 J/cm' ( = 5 min. of illumination) resulted in higher circulation 
damage scores than 600 J/cm' of light at the 24 h interval. Five minutes after 
the start of illumination, vascular spasms, circulating and occluding thrombi 
were observed. These direct vascular effects have also been reported during 
porphyrin based PDT (Star eta!., 1986; Reed eta/., 1988). 
Following 100 J/cm2 of light applied 1 h p.i., the tumor and normal tissue 
damage was sufficient to prevent tumor regrowth following retransplantation at 
day 7. Two hours post therapy re-transplantation yielded regrowth of the tumor, 
demonstrating the presence of viable tumor cells at this time. This observation 
agrees with the findings of Henderson (1992) that cells removed immediately 
after PDT can be viable in vitro, and stresses the role of tumor bed damage in 
determining the final outcome of photodynamic therapy. Histology performed 
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2 h post therapy revealed that individual tumor cells survived following PDT at 
1 h as well as at 24 h p.i. Probably the interval at which histology was 
performed was not optimal with respect to predicting the effectiveness of the 
therapy since one of the treatment schemes was effective in preventing tumor 
regrowth. 
Summarizing, BCA is useful, not only to induce tumor necrosis in PDT but for 
tumor detection by fluorescence as welL It induces selective fluorescence from 
5 to 120 min. p.i. in mammary tumors in the present model. In this respect and 
in this model, BCA is a much better tumor localizer than HPD. In vivo 
fluorescence of BCA can be used to determine a suitable time interval between 
i.v. administration of the dye and the subsequent therapeutic illumination of 
tumor tissue. The therapeutic ratio of the dye can be increased by making use of 
the photobleaching properties of the dye. In vitro, a 50% decrease of the 
absorption at 760 nm is observed after 86 Jlcm2 (unpublished data J.J. S.J. At 
the end of the therapeutic treatment viable tumor cells must be present as 
immediate retransplantation always results in tumor regrowth. Vascular damage 
appears to be a prerequisite to obtain tumor control with BCA. Determining the 
optimum sensitizer dose and interval between drug administration and therapy 
should be the subject of further study. 
Protoporphyrin IX as an endogenous photosensitizer 
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PHOTOSENSITIZING PROPERTIES OF PROTOPORPHYRIN IX 
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introduction 
In recent years a number of fluorescent dyes have been proposed and tested 
preclinically as photosensitizers for photodynamic therapy (PDT). Compared to 
porphyrins these "second generation" photosensitizers are often reported to 
cause less skin photosensitivity and they can be activated with light at 
wavelengths where tissue penetration is deeper than with the light used for 
porphyrins so that larger volumes can be treated. For recent reviews see: van 
Lier (1990a), Gomer (1991), Rosenthal, (1991), Henderson, (1992) and Moan 
11992). Following systemic administration exogenous photosensitizers like HPD 
and Photofrin"' also localize in tissues other than the target tissue. Therefore, 
phototoxic side effects can be expected. 
A different approach to photosensitize neoplastic tissue is to administer a 
specific precursor, stimulating the neoplastic tissue to synthesize its own 
photosensitizer. In the biosynthetic pathway of heme, 5-aminolevulinic acid 
(ALA) is a precursor of protoporphyrin IX IPpiX), which in turn is transformed 
into heme. 
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Figure 1. Simplified biosynthetic pathway for heme. Fluorescing and photosensitizing 
compounds are enclosed in rectangles, with protoporphyrin IX highlighted. The 
5-amino/evu/inic acid/heme feedback control is indicated by a dotted arrow. The 
principal biosynthetic route for ALA-induced protoporphyrin IX is indicated by the large 
arrows. (redrawn from Kennedy and Pottier, 1992} 
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The accumulation of PpiX in humans is associated with cutaneous 
photosensitivity seen with protoporphyria. Hence PpiX is an effective 
photosensitizer. Heme biosynthesis is essential to life and occurs in all aerobic 
cells (Fig. 1 ). Different cells however, differ in their heme generating capacity. 
The synthesized heme inhibits the synthesis of ALA from glycine and succinyl 
CoA by 5-aminolevulinic acid synthetase. Administering exogenous ALA 
bypasses this feedback control. 
Rate limiting steps such as the conversion of PpiX into heme by ferrochelatase 
which by itself is a slow process, can then result in an accumulation of PpiX 
inside cells. in regenerating tissues and in various malignant tissues the 
porphobilinogen deaminase (PBGD) activity is often increased, whereas the 
ferrochelatase activity is decreased (Smith, 1987; van Hillegersberg eta/., 1992; 
Leibovici eta!., 1988). Therefore, by providing the appropriate precursor, and by 
the activity status of key enzymes, malignant cells can generate and accumulate 
their own photosensitizer. 
ALA is hydrophillic and is therefore well suited to be administered systemically 
or to be dissolved in a cream for topical administration. PpiX on the other hand 
is hydrophobic, has a high affinity for membranes and therefore, once 
synthesized cannot easily be removed from the cell. Upon illumination and in the 
presence of molecular oxygen it causes cell death (Malik and Lugaci, 1987). 
When excited with light of a suitable wavelength it also shows fluorescence, 
thus combining the properties of a fluorescent tumor localizer and a 
photosensitizer for PDT. 
In vivo, following systemic administration, ALA causes the accumulation of 
PpiX in tumor tissue. The photosensitizer even accumulates in tumors growing 
in liver tissue to a higher extent than the host tissue (van Hillegersberg et a/., 
1992), the reverse of what is seen when HPD or Photofrin® are used as 
photosensitizers. 
This chapter describes preliminary in vivo studies of the development and 
decay of ALA generated protoporphyrin IX fluorescence. Also the effects of a 
treatment light dose on the normal and tumour tissue vasculature have been 
investigated. The results are discussed in relation to the clinical experience 
concerning topical ALA-PDT in our hospital. 
PpiX as tumor localizer 
The fluorescence kinetics and photodynamic effects of endogenously formed 
PpiX were studied in vivo using the window chamber model. Briefly, a syngeneic 
mammary carcinoma was transplanted intracutaneously in an observation 
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chamber mounted on the back of a female WAG/RIJ rat. Following i.v. 
administration of ALA (100 mg/kg) the fluorescence of the synthesized PplX 
was monitored up to 4.5 hours post injection (p.i.). Fluorescence was excited at 
514.5 nm, using 0.1 mW/cm' of excitation light and detected through a high-
pass filter above 665 nm. Fluorescence images were recorded using a two stage 
light intensified CCD (Charge Coupled Device) camera in combination with a 
computer based imaging system. 
Figure 2 shows the digitized fluorescence images before and at 4 intervals 
after i.v. administration of 100 mg/kg ALA. This picture differs from what is 
usually seen in the skin told chamber. With exogenous photosensitizers (van 
Leengoed eta!., 1990; van Leengoed eta!., 1992) a fluorescent angiogram was 
always observed which also serves as a check for successful drug delivery. No 
angiogram is observed with ALA which does not fluoresce. 
Figure 2. Digitized fluorescence images following i. v. administration 100 mg/kg of ALA 
before, (A}, at 30 min. IBJ, 60 min. ICJ, 780 min. IDJ and at 270 min. lEI p.i. 
Fluorescence at the site of the tumor develops while the large vessel (arrow} remains 
dark. 
From selected areas in the image, the average grey scale value can be 
determined and in Fig. 3 the fluorescence intensity in tumor tissue and normal 
tissue is shown as a function of time. The data are averages of six animals. 
F!uorescence in the tumor area becomes observable at 30 min. p.i. and reaches 
peak values at about 150 min. At 180 min. p.i. the fluorescence starts to 
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decrease and "selectivity" is lost due to the increase of fluorescence in the 
normal tissue. Between 60 and 150 min. p.i. the largest differences between 
tumor and normal tissue are be found. Twenty four hours post injection PpiX 
fluorescence has disappeared. Interestingly, when ALA was administered 
intraperitoneally in two animals, the same pattern was found. 
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Figure 3. Tissue fluorescence of following i.v. administration of 100 mg/kg b.w. ALA. 
Values are calculated from the digitized images for areas of tumor and normal tissue 
and averaged over six animals. 
Figure 4 shows the fluorescence of a basal cell carcinoma of a patient with basal 
cell naevus syndrome, about three hours after topical application of ALA. The 
photograph was taken at the beginning of the irradiation using the treatment 
light to excite the fluorescence. ALA was dissolved in a water based cream 
!25 % w/w) and applied to the lesion which was then covered with thin gauze 
and subsequently with adhesive plastic foil !Opraflex®). This cover protects the 
clothing, prevents the undesired removal of the cream and evaporation of the 
solvent ensuring optimal uptake of ALA. The fluorescence reveals the 
localization of the protoporphyrin, clearly demarcating the lesions in the 
irradiated area. The small fluorescent spots mark the hair follicles which are also 
known to accumulate PpiX following topical ALA application (Goff eta/., 1992). 
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Figure 4. Fluorescence image of Pp/X in human basal cell carcinoma following a three 
hour application period and excitation with 514.5 nm light at 70 mW/cm2• The image 
was recorded at the beginning of the irradiation through an OG 570 high pass filter. 
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Figure 5. Reduction of fluorescence caused by photobleaching of the photosensitizer 
due to excitation measured in two different spots. The solid line is a fit of the function 
A + B exp(-C x D) to the data points, where A .. B, C are contstants obtained from the 
fit and D is the light fluence IJ/cm2}. It shows the exponential decay of fluorescence as 
a result of irradiation. 
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Irradiation causes the destruction of the photosensitizer as a result of the 
photochemical reaction. The fluorescence that is emitted decreases and this 
phenomenon might be utilized to monitor the progress of the treatment. If the 
fluorescence has disappeared, so has the PpiX and further irradiation is useless. 
Figure 5 shows the decreasing intensity of fluorescence as a result of 
photobleaching. 
Note that there is an exponential decay of fluorescence and that the decreasing 
levels of fluorescence approaches a background level of about 110 nW/cm', 
presumably the tissue autofluorescence. Taking this into account already after 
approximately 24 J/cm' of treatment light, the PpiX fluorescence intensity has 
decreased to 37% of its starting value. 
PpiX as a photosensitizer for PDT 
Because the photosensitizer originates in the cell, cellular effects are expected to 
dominate. However, following systemic ALA administration vascular effects of 
PDT have been observed in our window chamber model. 
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Figure 6. Averaged vascular damage score of six animals following a therapy dose of 
100 J/cm' 117 min x 100 mW/cm'), at 514 nm in the in vivo skin fold chamber model, 
2 h p.i. of 100 mg/kg b. w. ALA i. v .. A maximum score of 8 corresponds with no 
observable circulation, whereas a value of 0 means no observable effect. 
Endothelial cell damage due to the treatment can therefore not be ruled out. 
Already during the first 5 min. of irradiation the circulation damage score has 
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increased to about 50 % of its maximum (Fig. 6). Only minor differences in 
damage between tumor tissue and normal tissue were observed. Maximum 
damage scores were not observed and circulation returned to normal during the 
next few days following treatment. Following a "regular" HPD-PDT treatment 
with i.v. administered photosensitizer, the vascular effects such as extravasation 
of blood and stasis can be much more pronounced depending on drug and light 
dose. In this form of treatment the vasculature is a known target (Star et a!., 
1986; Selman et a!., 1984). 
Twenty four hours following ALA-PDT some tissue necrosis of the tumor in 
the in vivo model has been observed. These observations show that PDT using 
systemically administrated ALA leads to vascular damage but that the 
combination of ALA dose, light dose and interval between administration and 
irradiation insufficient to cause tumor necrosis. The effects seem to occur too 
rapidly to be entirely attributable to an inflammatory response to the treatment. 
In patients with superficial lesions, topical ALA-PDT seems to be more 
effective than in the vivo experiments using i.v. administered ALA, described 
above. A complete response rate of 79% has been reported for superficial basal 
cell carcinomas after a single treatment. When partia! responders received a 
second treatment the response rate increased to 95% (Kennedy and Pottier, 
1992). The route of administration, the type of tumor and perhaps the degree of 
vascularisation may play a significant role in the differences between clinical 
data and in vivo experiments. In this respect it should be noted that clinically, 
20% ALA was used for topical administration (Kennedy and Pottier, 1992). 
In our institute patients receive 25 % w/w ALA in a water based cream and a 
light dose of 75 J/cm' (dose rate between 50-150 mW/cm2). Often large areas 
of skin have to be irradiated. Therefore, much light is needed and green light 
from an argon laser at 514.5 nm is used in such cases. Although tissue 
penetration of light at this wavelength is limited, the tissue penetration of ALA is 
believed to be the real limiting factor. Of course only superficial lesions can be 
effectively treated in this way. Soon after the beginning of the light treatment, 
the patients report varying levels of discomfort, such as stinging or tingling of 
the treated area, which usually decreases within minutes during treatment. 
These sensations vary from patient to patient, and also between treatment sites. 
When the treatment was finished, edema and erythema were usually observed in 
the entire area of ALA application, with a histamine "flare" that extended 
beyond this area. The lesion itself often showed a slightly blue discoloration and 
there may be some exudate. These findings resemble those reported by Kennedy 
(1992). 
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In the period following ALA-PDT the scab that has formed will fall off 
revealing a normal skin. Sometimes there is hyperpigmentation in the treated 
area and in the case of basal cell carcinoma it may take several months before 
the redness of the former lesion fades. The scarring is minimal and even after 
treating a superficial tumor recurrence in a skin graft the skin healed we!!. 
Concluding remarks 
Clinical PDT using topical ALA is currently restricted to the superficial skin 
lesions because of the limited depth of penetration of ALA. New formulations of 
ALA might enhance its penetration depth in tissue without interfering with the 
accumulation of PpiX in tumor cells. 
The synthesized photosensitizer disappears within 24 h, independent of the 
route of administration. When necessary the treatment can therefore be 
repeated within 48 h. ALA itself is not photodynamically active and not toxic in 
the concentrations used. ALA can be applied topically and at least in vivo it is 
possible to administer it i.v. and even orally. Topical administration will minimize 
side effects. When ALA is administered systemically, vascular effects are 
observed in our in vivo model, suggesting that vascular targets (endothelium, 
leucocytes) do exist for this type of treatment. 
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Chapter 8 
GENERAl DISCUSSION 
In this thesis, a number of in vivo observations have been reported regarding 14 
fluorescent dyes studied for tumor localization and/or photodynamic therapy 
(PDT). In this chapter the results are summarized and the fluorescence 
pharmacokinetics and photodynamic properties of these dyes are discussed. 
Fluorescence localization 
Ideally all photosensitizers eligible for PDT should show fluorescence and 
generate singlet oxygen. These features, in combination with the retention of 
the photosensitizer in malignant tissue and the possibility of local activation 
make PDT a potential new modality for cancer therapy. The localizing properties 
of photosensitizers can be employed for the detection of tumor tissue and it is 
evident that early recognition of malignant tissue will increase the success rate 
of cancer therapies. 
Fluorescence localization opens possibilities tor such early detection and in 
principle permits determination of the extent of the disease prior to treatment. 
The latter can be very useful when dealing with multifocal lesions, areas of field 
cancerization or invasive processes that need additional treatment after surgical 
debulking. It should be noted however that when fluorescence localization is 
considered, false positive and false negative fluorescence are likely to be 
encountered. Histology should therefore always be performed to ascertain the 
pathological status of these fluorescent areas. 
Hydrophillic dyes 
Acridine Red (Chapter 2) is a hydrophillic dye. It has a high fluorescence yield, 
localizes in tumor tissue and disappears from the circulation within minutes. The 
cellular site of localization has not yet been elucidated. At the initial dose of 
1 0 mg/kg this dye was sometimes associated with mortality but when the dose 
was reduced to 2 mg/kg, toxicity or morbidity was never observed. Because of 
the short half life in the circulation, this dye unfortunately will not localize in 
areas of the tumor where the circulation is (temporarily) blocked, a phenomenon 
not rare in larger tumors. 
A recently proposed method of photosensitization that is completely different 
from administering exogenous photosensitizers is to use a water soluble 
precursor of heme (AlA) and allow the (tumor) cells to generate their own 
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(hydrophobic) photosensitizer (PpiX, Chapter 7). This strategy results in 
fluorescence at the site where PpiX is synthesized without causing detectable 
fluorescence in the vasculature. All other dyes discussed in this thesis are more 
or less hydrophobic or are mixtures with varying hydrophobic /hydrophillic 
properties. 
Hydrophobic dyes 
When brought in an aqueous environment, hydrophobic dyes have a strong 
tendency to aggregate, making them photodynamically inactive. Three 
approaches have been used to prevent hydrophobic photosensitizers of 
becoming inactive. 
1. The hydrophillic properties of a dye can be increased by adding sulphonate 
groups to the macrocycle of the molecules. This approach has been used for 
AIPhcTS' (chapter 2) and the six metallosulphonated phthalocyanines (MPcS", 
chapter 3 and 4). 
2. Alternatively, before administration hydrophobic dyes can be incorporated 
into unilamellar liposomes as was done with ZnPc (chapter 5). 
3. They can also be administered using an emulsion like cremophor as was done 
with BCA (chapter 6). Following administration, these hydrophobic dyes tend to 
interact with serum proteins which can favour cellular uptake through receptor 
mediated transport. Compared to hydrophillic dyes they are retained in the 
circulation and therefore available to the tissue for a considerably longer time. 
In general, following systemic administration of the fluorescent dyes, a similar 
pattern of fluorescence kinetics has been observed. Immediately post injection a 
fluorescent angiogram develops. This is followed by a gradual decrease of 
fluorescence in the circulation. During this period of decrease, fluorescence at 
the site of the tumor becomes noticeable. Finally, fluorescence of the 
surrounding normal tissue starts to increase, usually causing the fluorescence of 
tumor and blood vessel relative to the normal tissue fluorescence to decrease. 
Three exceptions to this pattern are formed by: 
1. Ph II (Chapter 2): Here, fluorescent monomers are practically absent but 
fluorescence in the blood vessels increases up to 2 h p.i. This is probably caused 
by hydrolysis in vivo that leads to the formation of monomers. 
2. ZnPc incorporated into liposomes (chapter 5): Following administration and 
like Ph II, fluorescence in the blood vessels increases until 2 h post injection. 
10ld notation for a commercial preparation, consisting of a mixture of AIPcSn (n=1-4) with an 
average degree of sulphonation of 3, which in the literature has been referred to as aluminium 
phthalocyanine tetrasulphonate. 
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Twenty four hours after administration fluorescence in the tumor but also in the 
circulation can be observed. The low levels of fluorescence of the 
photosensitizer in the normal tissue probably contribute to this degree of 
selectivity. The dye effectively localizes in the tumor but also becomes strongly 
associated with serum proteins. 3. ALA (Chapter 7): This precursor of 
protoporphyrin (PpiXI does not fluoresce and therefore no fluorescence 
angiogram can be observed upon systemic administration. The fluorescent 
hydrophobic PpiX becomes only observable at sites where it is being 
synthesized. 
Tumor tissue localization 
Photosensitizers should have a certain degree of selectivity towards tumor tissue 
and therefore should not (or hardly) be retained in normal tissue. In general two 
factors seem to determine the practical use of photosensitizers for tumor 
localization. 
1. The monomeric form of a photosensitizer has the highest fluorescence yield. 
Therefore, a photosensitizer should preferably be active in its monomeric form. 
Fluorescence localization can than be expected to correlate with the site of 
action of PDT. Because of the opacity that varies between different tissues and 
because of fluorescence quenching, it will be difficult to asses the actual dye 
concentration using fluorescence. HPD and Ph II (Photofrin®) are 
photodynamically active in their dimeric and oligomeric components. Although 
these dyes are used for fluorescence localization there can probably be no 
correlation between the therapeutic effect and the presence of fluorescence. 
HPD fluorescence exists due to its contamination with monomers and 
fluorescence of Photofrin® is probably caused by conversion or degradation of 
the dimeric or oligomeric molecule in vivo. Theoretically these two dyes should 
therefore be regarded unsuitable for a combination of localization and treatment. 
2. The second factor to consider is that dyes like Up I (Chapter 2) which readily 
dissolve in water are also "washed" away more easily, reducing their 
"bioavailability". This implies that the more hydrophillic dyes, which are easy to 
dissolve and administer, will have to be taken up quickly as they will be available 
to tissue for only a short period of time. The interval during which localization 
can take place is therefore limited. Consequently, due to the short exposure, 
possible side effects could also be expected to be limited. 
Except for AIPcS2 and AIPcS4 (Chapter 31 after administration of the dye, 
fluorescence maxima in the circulation always. exceeded the fluorescence 
maxima in the tumor area. Aggregation of the lower sulphonated dyes upon 
administration and differences in fluorescence yield between plasma bound and 
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interstitially bound AlPeS" are expected to play an important role in these 
observations. Especially the presence of an extra axial ligand can be of great 
influence on aggregation. In vivo the relation between lipophillicity of the dye 
and tumor uptake is the inverse of what is found in vitro. The extracellular 
matrix and tumor stroma apparently are important factors in retention of the 
higher sulphonated phthalocyanines in vivo. 
The highest tumor tissue to normal tissue ratio (ratio of 4) has been observed 
with ALPcS2 and AIPcS4 • When muscle tissue would have been used as the 
reference normal tissue these ratios could have been much higher. Muscle tissue 
hardly retains any photosensitizer which makes it an unsuitable reference to 
express tumor to normal tissue ratios. In cases where tumors after HPD 
administration had equal or even lower levels of fluorescence than the subcutis 
of the skin fold chamber, the tumor fluorescence exceeded that of the 
background when the tumor was placed on the muscle tissue. (Chapter 2). 
The distribution of fluorescence for Up I, AR, HPD, Ph II and AIPhcTs was 
only rated visually, therefore no tumor to normal tissue ratios could be 
calculated. These ratios of the remaining 8 photosensitizers can be ranked from 
high to low as: AIPcS2 > AIPcS4 > ZnPcS4 > BCA > ZnPc-lip > AIPcS1 > 
ZnPcS1 > ZnPcS 2 • In this ranking order HPD en Ph II would probably be placed 
between ZnPcS, and ZnPcS,. 
Studying the photosensitizing properties of BCA, the concept of using 
fluorescence kinetics to determine a therapeutical window into which 
localization and of treatment can take place has been brought into practice in 
chapter 6. No fluorescence localization could be observed 24 h p.i. and 
treatment at this interval appeared to be unsuccessful. From the fluorescence 
pharmacokinetics of the dye a new treatment interval at 1 h p.i. was chosen. At 
this interval tumor fluorescence was still high, whereas fluorescence in the 
circulation was already decreasing. 
Photodynamic properties 
As was stated above an ideal photosensitizer should combine fluorescent and 
photodynamic properties. Both Up I and AR (Chapter 2) are photodynamically 
inactive and therefore do not qualify as photosensitizers for PDT. However their 
tumor localization, especially of dyes with qualities like AR but less toxic, might 
be utilized for screening purposes. The absence of photodynamic activity could 
then be regarded favourable. All other dyes discussed here demonstrated 
photodynamic activity in various degrees. 
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Comparing these different dyes seems to be almost impossible. Each dye has 
its own optimum drug dose, its optimum interval between administration and 
treatment and its optimum excitation wavelength. This thesis shows that each 
of these three factors can vary between the different photosensitizers. 
Activating wavelength 
All phthalocyanines and also BCA differ from porphyrins with respect to the 
maximum wavelength (675 and 760 nm respectively) at which the dye can be 
activated. The therapeutical benefits of this property, i.e. deeper tissue 
penetration of the activating light, could not be established in the in vivo model 
which is only 0.5 mm thick. Their photosensitizing properties in terms of 
fluorescence localization and their ability to cause tumor necrosis however have 
been demonstrated in chapters 3-6 of this thesis. 
Cellular effects 
The direct cytotoxic effect of PDT on tumor cells was estimated by histology 
and by retransplantation, where the treated area was removed from the chamber 
and implanted subcutaneously in the flank of the same animal. Direct effects on 
individual tumor cells were never sufficient to prevent tumor regrowth. Two 
hours post therapy, vital tumor cells were always observed in histology and after 
retransplantation, tumor regrowth always occurred. This regrowth was only 
prevented when retransplantation took place at the end of the observation 
period, 7 days after the treatment light dose. When at the end of this 
observation period both the tumor and the normal tissue had not become 
necrotic, tumor regrowth again was observed. 
Vascular effects 
The mechanism of photodynamic damage to the vasculature that was seen with 
the photosensitizers mentioned in this thesis, was similar to the photodynamic 
damage that was observed when HPD or Ph II were used. 
Tumor vessel damage seems to occur earlier during treatment than the 
damage to normal tissue vessels. Part of the difference between the vascular 
damage score of normal tissue and of tumor tissue might be explained by the 
fact that the normal tissue score also included damage to larger venules and 
arteries which were absent in the tumors. These "larger" normal vessels usually 
show more resistance to PDT induced damage than capillaries. Differences were 
found with respect to the occurrence of thrombi and the degree of constriction 
of the larger vessels (chapter 4-6). 
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Vascular effects were also observed when PpiX was activated after systemic 
ALA administration (chapter 7). These vascular effects could originate from 
indirect (inflammatory) effects as a result of treatment. However, they occur 
within minutes after the start of the irradiation and therefore indicate that 
possibly also vascular targets exist for this form of treatment. It should be noted 
that so far in patients ALA is used only topically. The experimental data 
presented here are based on experiments with systemically administered ALA. 
Following treatment and using a specific drug dose, interval to treatment and 
light dose, tumor necrosis was achieved using ZnPc in liposomes, BCA, ALPcS2 
and both MPcS1 • Tumor necrosis without in situ recurrence was only observed 
when also the surrounding normal tissue of the chamber had become necrotic. 
Even at the low dose of 0.14 mg/kg, liposome bound ZnPc was effective. This 
demonstrates that using a delivery system like liposomes allows for a much 
more efficient administration of a lipophi!Jic photosensitizer. So far it is not 
known what portion of an administered dose is actuaHy involved in 
photosensitizing the tissue. 
When all MPcS, are considered, it appears that damage (to the vasculature) 
increases with increasing degree of lipophilicity (Chapter 4). This is in agreement 
with what has been found in vitro for tumor cells. On the other hand 
fluorescence localization in the tumor appears to decreases with increasing 
degree of lipophillicity (Chapter 3). It might therefore be possible to use MPcS, 
that have low photodynamic activity for tumor localizing purposes. Only AIPcS 2 
seems to combine favourable properties for fluorescence localization and 
photodynamic therapy. 
Vascular stasis resulting from PDT is perhaps not the effect that was intended 
for a therapy based on tumor localization of the photosensitizer. However, the 
hypoxia that results from the vascular effects can resu!t in additiona[ necrosis of 
tumor cells unaffected by the primary treatment. Vascular damage originating 
from PDT should therefore not be regarded as undesired side effects, but should 
be studied further in order to make maximum use of it. The skin fold chamber 
model utilized in the previous chapters proved to be ideally suited for studying 
these vascular effects resulting from therapy as well as fluorescence 
pharmacokinetics. 
Fluorescence pharmacokinetics can provide us with important information 
about the distribution of the dye over the tissues after administration. This can 
help to determine the therapeutical window during which localization and 
therapy can take place. It also appears that for many photosensitizers there is an 
effective combination of drug dose, light dose, and interval. 
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Een belangrijke taak van het kankeronderzoek is het ontwikkelen van 
behandelvormen die tumorspecifiek zijn. Fotodynamische therapie (PDT, afgeleid 
van "Photodynamic therapy") is zo'n nieuwe behandelingsvorm. Deze maakt 
gebruik van lichtgevoelige stoffen, fotosensitizers genaamd, die hun toxiciteit 
ontwikkelen als ze geactiveerd worden door Iicht. 
Bij fotodynamische therapie wordt een lichtgevoelige (kleur)stof meestal via de 
bloedbaan (systemisch) toegediend. Daarnaast worden lokale toedieningswijzen 
onderzocht. In het geval van een systemische toediening blijft er na verloop van 
tijd meer van deze stof in tumor weefsel achter dan in het omgevende normale 
weefsel. Als na 1 of 2 dagen het tumor weefsel wordt belicht met Iicht van de 
juiste golflengte en met een voldoende fluentie tempo (mW /cm2) en dosis 
(J/cm2), leidt dit tot een cytotoxische reactie die uiteindelijk weefsel necrose tot 
gevolg heeft. Omdat er minder van de lichtgevoelige stof in het omgevende 
normale weefsel zit en omdat de lichtdosis lokaal wordt toegediend beschikt de 
therapie als het ware over een tweeiedige selectiviteit. 
Wanneer een lichtgevoelige stof wordt geactiveerd kan deze oak fluorescentie 
gaan vertonen. De stof gaat dan zeit Iicht uitzenden. Deze fluorescentie kan 
vervolgens worden gebruikt om de lichtgevoelige stoffen op te sporen. 
Gecombineerd met hun retentie in tumor weefsel, kunnen deze stoffen dus 
zowel worden gebruikt voor therapie als voor tumor-lokalisatie op basis van 
fluorescentie. 
Hematoporphyrine derivaat (HPD) en Photofrin° (een commercieel preparaat 
dat verrijkt is in de actieve component van HPD) zijn de fotosensitizers die 
momenteel klinisch geevalueerd worden. Deze lichtgevoelige stoffen voldoen 
echter niet aan de eisen van een ideate fotosensitizer. Zo hebben ze een lage 
extinctiecoefficient in het golflengtegebied dat klinisch relevant is. Dit houdt in 
dat deze stoffen niet efficient geactiveerd kunnen worden met Iicht dat in staat 
is meer dan enkele millimeters in weefsel door te dringen. Het behandelen van 
grote volumina is daardoor een probleem. Daarnaast is de tumor-specificiteit van 
deze stoffen niet groat. Oak gezond weefsel houdt deze stoffen vast en dat 
geeft vooral problemen met de huid. Na toediening van HPD of Photofrin® moet 
men rekening houden met gevoeligheid van de huid voor Iicht die 4 tot 6 weken 
kan duren. Daarnaast zijn HPD en Photofrin° mengsels van porphyrines waarvan 
de onderlinge verhoudingen ten gevolge van de bereiding niet constant hoeven 
te zijn. Tenslotte is de fluorescerende component van HPD of Photofrin° niet 
dezelfde component die verantwoordelijk lijkt voor de fotodynamische activiteit. 
De fluorescentie hoeft daardoor niet overeen te komen met de plaats van de 
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fotodynamisch actieve component. Ten aanzien van al deze aspecten zouden de 
nieuwe (tweede generatie) fotosensitizers verbeterd moeten worden. 
In dit proefschrift worden 14 fluorescerende stoffen onderzocht op hun 
gebruik voor tumor-lokalisatie met behulp van fluorescentie en op hun 
fotodynamische activiteit. 
Materiaal en methode. Bij het onderzoek is gebruik gemaakt van een in vivo 
model dat bestaat uit een observatiekamertje (circa 10 mm diameter) dat in een 
huidplooi van een rat is geplaatst. In dit kamertje, waarin een dun laagje 
subcutaan weefsel zit, kan een stukje transplanteerbaar tumor weefsel geplaatst 
worden. Onder een microscoop kan dan, met een kleine vergroting, de circulatie 
in de tumor en het omgevende weefsel bestudeerd worden. Op deze wijze kan, 
na intraveneuze toediening van een fluorescerende stof, het verloop van de 
fluorescentie in vaten, tumor en omgevend weefsel worden gevolgd. 
Behalve voor het onderzoek naar de fluorescentie-kinetiek is het kamertje ook 
geschikt om de fotodynamische activiteit van deze stoffen te onderzoeken. Met 
name het effect van de therapie op de vaten, in de loop van de tijd, is met dit 
model goed te beoordelen. Na de behandeling kan vervolgens histopathologisch 
onderzoek of transplantatie van de inhoud van het kamertje in de flank van het 
dier .. uitsluitsel geven over de aanwezigheid van vitale tumor cellen in het 
weefsel. 
Voor het fluorescentie onderzoek is een detectiesysteem gebouwd dat 
geschikt is om met weinig Iicht fluorescentie op te wekken en te detecteren. Op 
deze manier kan worden voorkomen dat de lichtgevoelige stat al tijdens het 
fluorescentie onderzoek wordt geactiveerd. 
Hoofdstuk 2. In dit hoofdstuk worden de lokaliserende eigenschappen van 5 
lichtgevoelige stoffen onderzocht. Drie stoffen met fotodynamische activiteit: 
hematoporphyrine derivaat (HPD). Photofrin II (Phil) en aluminium phthalocyanine 
tetrasulphonaat (AIPhcTS). Van deze drie heeft de laatste de beste 
tumor-lokaliserende eigenschappen. In tegenstelling tot deze fotosensitizers zijn 
de andere twee stoffen hydrofiel, hetgeen betekent dat ze goed in water 
oplossen. Zowel Acridine Rood (AR) als Uroporphyrine I (Upl) vertonen 
tumor-lokalisatie en verdwijnen daarbij snel uit de circulatie. Upl wordt echter 
nauwelijks vastgehouden in tumor weefsel en daarom is de fluorescentie van de 
tumor maar zeer kart waar te nemen. AR fluorescentie blijtt veel Ianger 
waarneembaar maar de stof blijkt daarnaast oak giftige eigenschappen te 
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hebben. Vooral de resultaten met AIPhcTS, dat zowel goede tumor lokaliserende 
als fotodynamische eigenschappen bezit, gaven aanleiding tot verder onderzoek. 
Hoofdstuk 3 en 4. In een waterige omgeving, die nodig is om stoffen 
intraveneus toe te dienen, hebben phthalocyanines de neiging om te aggregeren. 
Hierdoor worden ze fotodynamisch inactief. Om deze stoffen meer hydrofiele 
eigenschappen te geven kan, door middel van het aanbrengen van 
sulfonzuurgroepen, hun chemische structuur worden gewijzigd. De stoffen 
kunnen dan oak in water hun eigenschappen als fotosensitizer behouden. in 
hoofdstuk 3 wordt de fluorescentie farmaco-kinetiek van een zestal 
phthalocyanines, varierend in hun graad van sulfonering (1, 2 of 41 en centraal 
metaalion (AI3+ of Zn 2 +), onderzocht. Het blijkt dat tumor-lokalisatie op basis 
van fluorescentie toeneemt als het aantal sulfonzuurgroepen 
Phthalocyanines met aluminium als centraal metaal ion 
lokaliserende eigenschappen te hebben dan die met zink. 
oak toeneemt. 
blijken betere 
De fotodynamische activiteit van deze zes stoffen is beschreven in 
hoofdstuk 4. Wat deze eigenschap betreft blijkt dat laag gesulfoneerde 
phthalocyanines meer (vaat)schade veroorzaken dan hager gesulfoneerde 
phthalocyanines. Oak nu hebben phthalocyanines met aluminium als centraal 
metaalion meer effect. 
Hoofdstuk 5. Een andere manier om hydrofobe stoffen toe te dienen is ze op te 
lassen in de lipidenlaag van liposomen. De liposomen worden vooral opgenomen 
door low density lipoproteins (LDL), waarvan de opname in tumor cellen hoog is. 
Op deze wijze blijkt zink-phthalocyanine (ZnPc) al in een !age concentratie als 
fotosensitizer effectief te zijn. Daarnaast was het ook met deze lage concentratie 
mogelijk de tumor met behulp van fluorescentie te lokaliseren. In tegenstelling 
tot de andere lichtgevoelige stoffen die onderzocht werden was ook na 24 uur 
nag fluorescentie in de circulatie waarneembaar. 
Hoofdstuk 6. Een derde manier om hydrofiele stoffen toe te dienen is door ze in 
een emulsie op te nemen. Deze methode is toegepast voor bacteriochlorine a 
(BCA). Deze lichtgevoelige stof heeft als gunstige eigenschap dat het absorptie 
maximum van deze stof bij 760 nm ligt. Ten opzichte van de andere 
fotosensitizers is deze golflengte hoog waardoor het theoretisch mogelijk is met 
het activeringslicht dieper in het weefsel door te dringen. In dit hoofdstuk 
worden de eigenschappen van BCA als fotosensitizer met betrekking tot 
fluorescentie en fotodynamische activiteit beschreven. De fluorescentie-kinetiek 
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is gebruikt om een geschikt tijdsinterval te vinden tussen toediening van de 
fotosensitizer en de behandeling met Iicht. 
Hoofdstuk 7. In tegenstelling tot (exogene) fotosensitizers die in het lichaam 
gebracht moeten worden kan fotodynamische therapie oak met een endogene 
fotosensitizer uitgevoerd worden. Protoporphyrine IX (PpiX) is een tussenprodukt 
van de haem synthese dat zowel fotodynamische als fluorescerende 
eigenschappen bezit. Wanneer een "precursor" van haem~ 5-aminolevuline zuur 
(ALA) in een overmaat aan (tumor) cellen wordt aangeboden, vindt er een 
ophoping van PpiX in de eel plaats. ALA is hydrofiel en kan daardoor gemakkelijk 
worden toegediend. Dit kan zowel systemisch als met een creme (lokaal) 
gebeuren. In dit hoofdstuk worden de voorlopige resultaten beschreven van in 
vivo onderzoek naar de fluorescentie-kinetiek van PpiX fluorescentie. Oak 
worden de vasculaire effecten van een therapeutische belichting onderzocht. 
Deze in vivo resultaten worden besproken in relatie tot de klinische ervaringen 
van lokaal ALA-PDT in ons ziekenhuis. 
Hoofdstuk 8. In dit hoofdstuk worden de resultaten van het onderzoek 
samengevat. De lichtgevoelige stoffen worden besproken met betrekking tot hun 
fluorescentie farmaco-kinetiek en fotodynamische activiteit. 
De fluorescentie farmaco-kinetiek kan ons belangrijke informatie geven over de 
verdeling van de lichtgevoelige stof over de weefsels als functie van de tijd. Op 
basis van deze informatie kan een raamwerk worden gedefinieerd waarbinnen 
diagnostiek op basis van fluorescentie en therapie plaats kan vinden. 
De vaateffecten blijken nog steeds doorslaggevend te zijn bij het bepalen van 
het uiteindelijke succes van de therapie. Het onderzoek naar de vaateffecten 
blijft daardoor van groot belang. Het lijkt er op dat er voor veel fotosensitizers 
een effectieve combinatie bestaat van de dosis van de stof, het interval tussen 
toediening en behandeling en de lichtdosis. 
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List of abbreviations 
ALA 5-Aminolaevulinic acid 
AlPeS" Aluminum "sulphonated phthalocyanine 
BCA Bacteriochlorin a 
DPPC Dipalmitoyl-phosphatidylcholine 
HOE Dihaematoporphyrin ether/ester 
HDL High density lipoproteins 
HP Haematoporphyrin 
HPD Haematoporphyrin derivative 
i.v. intravenous 
LDL Low density lipoproteins 
MPcS" Metallo "sulphonated phthalocyanine 
PDT Photodynamic therapy 
Ph Photofrin® 
Phil Photofrin II 
PplX Protoporphyrin IX 
PBS Phosphate buffered saline 
Pc Phthalocyanine 
p.i. post injection 
RH Rhabdomyosarcome 
RMA Mammary carcinoma 
Up I Uroporphyrine I 
ZnPc Zinc phthalocyanine 



